Phaseout DMD: A Phase 2 Clinical Study to Assess the Activity and Safety of Utrophin Modulation With Ezutromid in Ambulatory Paediatric Male Subjects With Duchenne Muscular Dystrophy (SMT C11005)
Phase: PHASE2
Conditions: Duchenne Muscular Dystrophy
Sponsor: Summit Therapeutics

Protocol Number: SMT C11005 
 
Official Title:  PhaseOut DMD: A Phase 2 Clinical Study to Assess the Activity
and Safety of Utrophin Modulation with SMT C1100 in
Ambulatory Paediatric Male Subjects with Duchenne Muscular
Dystrophy (SMT C11005)
  
 
NCT Number:  NCT02858362 
 
Document Date:  24Feb2017 

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 1 of 89
CONFIDENTIAL
Title:
PhaseOut DMD: A Phase 2 Clinical Study to Assess the Activity 
and Safety of Utrophin Modulation with SMT C1100 in 
Ambulatory Paediatric Male Subjects with Duchenne Muscular 
Dystrophy (SMT C11005) 
Effective Date:
24/Feb/17
Short Title: PoC Study to Assess Activity and Safety of SMT C1100 (Ezutromid) in 
Boys with DMD
Abstract: This is a Phase 2, open-label, study to assess the activity and safety of utrophin 
modulation with SMT C1100 administered twice-daily (bid) to paediatric male subjects 
with Duchenne Muscular Dystrophy (DMD).  
Study SMT C11005 will enrol approximately 55 patients in three cohorts. In Cohort 1 
approximately 30 patients with DMD, from UK and US sites, will receive 2.5 g SMT 
C1100 bid as a microfluidised aqueous oral suspension (F3). In Cohort 2 approximately 
10 patients will receive 1 g SMT C1100 bid as a powder for oral suspension (F6). These 
10 patients in Cohort 2 will be enrolled at US sites only. In Cohort 3, approximately 15 
patients, who have previously received SMT C1100 but who are not eligible for Cohort 1 
or 2, will be enrolled in a safety arm and undergo additional cardiac magnetic resonance 
scans and pulmonary function tests. The patients in Cohort 3 will be enrolled at UK sites 
only and will receive 2.5 g SMT C1100 bid as a microfluidised aqueous oral suspension 
(F3).
This study investigates the biological (pharmacokinetic/pharmacodynamic) and clinical 
effects of SMT C1100 in a DMD population. It also examines the long term safety 
profile, initially over 48 weeks but then for longer for those who agree to enter the 
Extension Phase (which will continue until either SMT C1100 is approved in the relevant 
countries or development of SMT C1100 is discontinued). This is a proof-of-concept 
study and as such aims to determine if SMT C1100 acts as seen in in vitro and pre-
clinical studies and modulates utrophin expression in muscles. This study will 
specifically investigate if the expected changes in utrophin have a demonstrable effect on 
leg muscles (determined by magnetic resonance imaging (MRI)).

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 2 of 89
CONFIDENTIAL
The information contained in this document is the property of Summit (Oxford) Limited 
(referred hereafter to as Summit) and may not be produced, published or disclosed to 
others without written authorisation from Summit. Summit is a wholly owned subsidiary 
of Summit Therapeutics Plc (www.summitplc.com).

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 4 of 89
CONFIDENTIAL
  
  
  

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 5 of 89
CONFIDENTIAL
INVESTIGATOR SIGNATURE PAGE
I agree to conduct this Study in accordance with the requirements of this document (the 
Clinical Study Protocol), the Study Reference Manual and also in accordance with the 
following: 
x
Declaration of Helsinki (revised version of Fortaleza, Brazil, 2013)
x
The International Council on Harmonisation of technical requirements for 
pharmaceuticals for human use (ICH) harmonised tripartite guideline regarding 
Good Clinical Practice (ICH-GCP E6 (R2) Consolidated Guidance, November 
2016) 
x
Local laws and regulations 
x
Any amendments to these regulations 
Investigator Name and Qualifications: _____________________________________
Investigator Signature
Date
[Investigator Affiliation]

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 6 of 89
CONFIDENTIAL
TABLE OF CONTENTS
PAGE
  
PROTOCOL SUMMARY...............................................................................................12
1.
INTRODUCTION....................................................................................................25
1.1.
Background ................................................................................................25
1.1.1.
Name and Description of the Investigational Medicinal 
Product........................................................................................27
1.1.3.
Summary of Clinical Studies in the Duchenne Muscular 
Dystrophy Population...................................................................31
1.1.4.
Study Conduct .............................................................................34
1.2.
Rationale ....................................................................................................35
1.3.
Potential Risks and Benefits to Human Subjects.........................................38
1.3.2.
Healthy Volunteer Safety Summary .............................................39
1.3.3.
Duchenne Muscular Dystrophy Patients Safety Summary ...........40
1.3.4.
Risk Mitigation in Study SMT C11005..........................................42
1.3.5.
Risk Benefit Statement ................................................................44
2.
OBJECTIVES.........................................................................................................45
2.1.
Primary Objectives......................................................................................45
2.2.
Secondary Objectives.................................................................................46
2.3.
Exploratory Objectives................................................................................46
3.
ENDPOINTS ..........................................................................................................46
3.1.
Primary Endpoints ......................................................................................47
3.2.
Secondary Endpoints..................................................................................47
3.3.
Exploratory Endpoints.................................................................................48
4.
STUDY DESIGN ....................................................................................................49
4.1.
Summary of Study Design ..........................................................................49
4.1.1.
Study Design ...............................................................................49
4.1.2.
Duration of Patient Participation...................................................50
4.2.
Stopping Rules ...........................................................................................51
4.2.1.
Study Stopping Rules ..................................................................51
4.2.2.
Individual Stopping Rules ............................................................51
5.
STUDY POPULATION...........................................................................................52

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 7 of 89
CONFIDENTIAL
5.1.
Number of Patients.....................................................................................52
5.2.
Eligibility Criteria .........................................................................................53
5.2.1.
Main Study...................................................................................53
5.2.1.1.
Inclusion Criteria.........................................................53
5.2.1.2.
Exclusion Criteria .......................................................54
6.
STUDY ASSESSMENTS AND PROCEDURES .....................................................56
6.1.
Screening Procedures ................................................................................56
6.1.1.
Medical History ............................................................................56
6.1.2.
Demographics .............................................................................56
6.1.3.
Nutritionist Appointment...............................................................56
6.2.
Pharmacodynamic Procedures...................................................................57
6.2.1.
Muscle Biopsy .............................................................................57
6.2.2.
Blood Biomarkers ........................................................................57
6.2.3.
Magnetic Resonance Imaging......................................................58
6.2.3.1.
Leg Scan....................................................................58
6.2.3.2.
Cardiac Scan..............................................................58
6.3.
Pharmacokinetic Procedures ......................................................................58
6.4.
Safety Procedures ......................................................................................59
6.4.1.
Twelve-Lead Electrocardiogram ..................................................59
6.4.2.
Echocardiogram...........................................................................59
6.4.3.
Vital Signs....................................................................................60
6.4.4.
Physical Examination...................................................................60
6.4.5.
Pulmonary Assessment ...............................................................60
6.4.6.
Laboratory Assessments .............................................................61
6.4.6.1.
Haematology and Coagulation Times.........................61
6.4.6.2.
Clinical Chemistry.......................................................62
6.4.6.3.
Additional Clinical Chemistry ......................................63
6.4.6.4.
Coagulation Parameters.............................................63
6.4.6.5.
Urinalysis....................................................................64
6.5.
Efficacy Procedures....................................................................................64
6.5.1.
North Star Ambulatory Assessment .............................................65
6.5.2.
10-Metre Run or Walk..................................................................65
6.5.3.
Six-Minute Walk Distance ............................................................65
6.5.4.
Paediatric Outcomes Data Collection Instrument.........................65
6.5.5.
Performance of the Upper Limb...................................................66
7.
LIFESTYLE AND/OR DIETARY RESTRICTIONS..................................................66
8.
INVESTIGATIONAL MEDICINAL PRODUCT.........................................................66
8.1.
Dosage and Administration.........................................................................66
8.1.1.
Dose Modification Guidelines.......................................................66
8.2.
Dose Rationale ...........................................................................................67
8.3.
Blinding.......................................................................................................70
8.4.
Packaging and Labelling.............................................................................70
8.5.
Preparation................................................................................................. 71
8.6.
Handling and Storage .................................................................................71
8.7.
Product Accountability and Assessment of Compliance..............................71
8.8.
Treatment of Investigational Product Overdose ..........................................71

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 8 of 89
CONFIDENTIAL
8.9.
Occupational Safety....................................................................................72
9.
CONCOMITANT MEDICATIONS AND NON-DRUG THERAPIES .........................72
9.1.
Permitted Medications ................................................................................72
9.2.
Prohibited Medications................................................................................72
10. PATIENT COMPLETION AND WITHDRAWAL......................................................73
10.1.
Patient Completion .....................................................................................73
10.2.
Patient Withdrawal......................................................................................74
10.2.1.
Patient Withdrawal from Investigational Medicinal Product ..........74
10.2.2. 
Patient Withdrawal from Study.....................................................74
10.3.
Treatment after the End of the Study ..........................................................75
10.4.
Screen and Baseline Failures .....................................................................75
11. ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS .....................................75
11.1.
Adverse Events...........................................................................................75
11.1.1.
Causal Relationship.....................................................................75
11.1.2.
Severity Criteria ...........................................................................76
11.1.3.
Reporting Adverse Events ...........................................................76
11.2.
Serious Adverse Events..............................................................................77
11.2.1.
Suspected Unexpected Serious Adverse Reactions ....................77
11.2.2.
Reporting Serious Adverse Events ..............................................77
12. DATA ANALYSIS AND STATISTICAL CONSIDERATIONS...................................79
12.1.
Data Analysis Considerations .....................................................................79
12.1.1.
Analysis Populations....................................................................79
12.1.2.
Treatment Comparisons ..............................................................79
12.1.3.
Interim Analysis ...........................................................................79
12.1.4.
Key Elements of Analysis Plan ....................................................79
12.1.4.1.
Pharmacodynamic Analyses ......................................80
12.1.4.2.
Pharmacokinetic Analyses..........................................80
12.1.4.3.
Safety Analyses..........................................................80
12.1.4.4.
Efficacy Analyses .......................................................81
12.1.5.
Missing, Unused and Spurious Data............................................81
12.1.6.
Reporting Deviations from the Statistical Plan .............................81
13. STUDY ADMINISTRATION....................................................................................81
13.1.
Regulatory and Ethical Considerations, Including the Informed 
Consent Process ........................................................................................81
13.2.
Data Monitoring Committee ........................................................................82
13.3.
Study Monitoring.........................................................................................82
13.3.1.
Access to Source Data ................................................................82
13.3.2.
Data Handling and Record Keeping.............................................83
13.4.
Provision of Study Results and Information to Investigators........................83
13.5.
Confidentiality of Study Patients ................................................................. 84
13.6.
Data Management ......................................................................................84
13.7.
Insurance, Indemnity and Finance ..............................................................85
14. REFERENCES.......................................................................................................86

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 9 of 89
CONFIDENTIAL
15. APPENDIX 1: INDUCERS OF CYP1A1, CYP1A2 SUBSTRATES OF 
CYP2B6 AND BRCP..............................................................................................88

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 10 of 89
CONFIDENTIAL
ABBREVIATIONS
6MWD
Six-minute walk distance
ABC
ATP-binding cassette protein
AE
Adverse event
ALT
Alanine aminotransferase
AST
Aspartate aminotransferase
aPTT
Activated partial thromboplastin time
AUC(0–t)
Area under the curve from time 0 to the last measureable 
concentration
AUC(0–tau)
Area under the curve from time 0 to the time of the next 
dose
BCRP
Breast-cancer resistance protein
bid
Bis in die (twice-daily)
BSEP
Bile salt export pump
C4
Į-hydroxy-4-cholesten-3-one
CHF
Congestive heart failure 
CK
Creatinine kinase
Cmax
Maximum observed concentration
CRF
Case report form
CYP
Cytochrome P450
DHD I
Dihydrodiol I
DHD III
Dihydrodiol III
DMC
Data monitoring committee
DMD
Duchenne muscular dystrophy
EC50
Half-maximal effective concentration
ECG
Electrocardiogram
ECHO
Echocardiogram
ECV
Extracellular volume
F2
Microfluidised aqueous oral suspension
F3
Microfluidised aqueous oral suspension (with xanthum 
gum)
F5
Aqueous oral nanosuspension
F6
Powder for oral suspension
FEV1
Forced expiratory volume in 1 second
FVC
Forced vital capacity
GCP
Good clinical practice
GLDH
Glutamate dehydrogenase
hERG
Human ether-à-go-go-related gene
ICH
International committee on harmonization
IEC
Independent ethics committee
IMP
Investigational medicinal product
INR
International normalised ratio
IRB
Institutional review board

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 11 of 89
CONFIDENTIAL
ITT
Intention-to-treat
LFT
Liver function test
LSLV
Last subject last visit
MATE
Multidrug and toxin extrusion protein
MDR
Multi-drug resistance gene
MEP
Maximum expiratory pressure
MIP
Maximum inspiratory pressure
MMP
Matrix metalloproteinase
MRI
Magnetic resonance imaging
mRNA
Messenger ribonucleic acid
MRP
Multi-drug resistance associated protein
MRS
Magnetic resonance spectroscopy
NADPH
Nicotinamide adenine dinucleotide phosphate
NOAEL
No observed adverse effect level
NSAA
North Star ambulatory assessment
OATP
Organic anion-transporting polypeptide
OCT
Organic cation transporter
PBPK
Physiologically based pharmacokinetics
PCF
Peak cough flow
PEF
Peak expiratory flow
PK
PoC
Pharmacokinetic
Proof of Concept
PODCI
Paediatric outcomes data collection instrument
PT
Prothrombin time
PUL
Performance of the upper limb
QTcF
QT interval, heart rate corrected using Fridericia’s formula
RNA
Ribonucleic acid
SAE
Serious adverse event
SNIP
Sniff nasal inspiratory pressure
SUSAR
Suspected unexpected serious adverse reaction
t1/2
TEAE
Terminal elimination half-life
Treatment Emergent Adverse Event
tid
Ter in die (three times daily)
tmax
Time of Cmax
UGT
Uridine 5'-diphospho-glucuronosyltransferase
ULN
Upper limit of normal

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 12 of 89
CONFIDENTIAL
PROTOCOL SUMMARY
Rationale 
This open-label study (SMT C11005) will be the first Phase 2 study of a utrophin 
modulator in boys with Duchenne muscular dystrophy (DMD). Previous studies with SMT 
C1100 have dosed for a maximum of 2 weeks whereas this study involves initially dosing for 
48 weeks and then for longer in an Extension Phase (which will continue until either 
SMT C1100 is approved in the relevant countries or development of SMT C1100 is 
discontinued). The primary objectives of this study are to evaluate changes in leg magnetic
resonance imaging (MRI) parameters over time as well as evaluate the efficacy and safety
of SMT C1100 in a larger population of boys with DMD. 
For Cohorts 1 and 2 this open-label proof of concept study will investigate the 
relationship between the SMT C1100 pharmacokinetic levels and utrophin modulation 
and muscle markers of regeneration as analysed in the biopsy. It will also investigate 
whether there is any relationship between drug concentration and change in muscle 
biomarkers. Further, this open-label concentration-response study will also examine 
whether the potentially observed utrophin modulation is correlated with improvements in 
markers of muscle disease progression, as indicated by leg MRI parameters (e.g., fat 
fraction in the leg), and/or in long term improvements in functional endpoints, such as the 
six-minute walk distance (6MWD). Results of this study will facilitate the design of 
future studies 
Unfortunately, there are patients who have taken part in prior SMT C1100 studies who 
now do not meet the entry criteria for Cohorts 1 or 2, and are most likely to be at risk for 
cardio-respiratory decline due to their older age. These patients will be enrolled in this 
study as Cohort 3. There is increasing recognition of the effect of cardiomyopathy on 
morbidity and mortality in DMD, and improved strategies are needed to change the 
natural history of declining left ventricular systolic function and to attenuate its sequelae. 
There is also a need to slow down the loss of respiratory function in patients with this 
disease [McNally et al. 2015]. Therefore Cohort 3 will examine whether any potentially 
observed utrophin modulation improves MRI cardiac parameters (such as extracellular 
volume fraction (ECV), left ventricular strain, left ventricular ejection fraction, end-
diastolic and end-systolic volumes (EDV), and late gadolinium enhancement of left 
ventricular mass) and respiratory function parameters (such as forced expiratory volume 
in 1 second (FEV1), forced vital capacity (FVC) maximum inspiratory pressure (MIP), 
maximum expiratory pressure (MEP) and peak expiratory flow (PEF)). Results from this 
cohort will also facilitate the design of a study in older patients.
SMT C1100 is thought to be of potential value in treating patients with DMD and has 
progressed into clinical development based on knowledge of its in vitro properties and 
identified pharmacodynamic effects in animal models. Ex vivo human studies and in vivo
mouse studies with SMT C1100 demonstrate that concentrations above 0.2 μM for 
several hours are enough for at least two-fold activation of the utrophin promoter 

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 13 of 89
CONFIDENTIAL
[Tinsley et al. 2011], and even lower concentrations of SMT C1100 increased in vitro
utrophin expression in myoblasts from DMD patients. However, it is currently unknown 
which in vivo target plasma concentrations in patients would lead to activation of the 
utrophin promoter with subsequent increase in muscle utrophin expression and whether 
continuous or an intermittent stimulation of the utrophin promoter is needed to provide 
clinical benefit.
The development of SMT C1100 in the clinic was initially hampered by low plasma 
exposure and interpatient variability associated with diet (SMT C11002). SMT C1100’s 
Phase 1 program employed multiple approaches to address early pharmacokinetic issues. 
Retrospective ad hoc analysis of DMD patients’ food diaries identified the potential for 
low fat diets to affect absorption, leading to the modified diet approach that improved 
absorption (SMT C11003) and supported taking the microfluidised oral suspension F3 
into a Phase 2 study. In previously reported studies of SMT C1100 in DMD patients 
(SMT C11002 and SMT C11003), results showed that SMT C1100, administered as a 
microfluidised formulation (F2 or F3), although having variable PK levels, was safe and 
well tolerated at doses up to 0.1 g/kg three times daily (tid) and 2.5 g twice daily (bid), 
with the 2.5 g bid dose considered suitable for further clinical development. Patients in 
Cohorts 1 and 3 of this study (SMT C11005) will receive the 2.5 g dose bid as a 
microfluidised aqueous oral suspension (F3). 
In the meantime, a reformulation Phase 1b study (SMT C11004) in DMD patients 
demonstrated that a powder for oral suspension (F6), markedly increased exposure. In 
Study SMT C11004 two newly developed formulations, (a nanosuspension (F5) and a 
powder for oral suspension (F6)), were administered orally to determine safety and 
pharmacokinetics in healthy volunteers. Both formulations were found to be safe and 
well tolerated in the healthy volunteers though transient elevations in liver function tests 
were seen, the significance of which is unknown. Based on review of the safety, 
tolerability and pharmacokinetic data, the powder for oral suspension formulation (F6) 
was chosen to have its safety and pharmacokinetics investigated in DMD patients. The F6 
formulation was administered to the DMD boys at doses of 0.25 g bid, 0.5 g bid and 1 g 
bid. Based upon the safety, tolerability and favourable pharmacokinetics a 1 g bid dose of 
the F6 formulation was chosen to be administered in Study SMT C11005, in a separate 
cohort of approximately 10 patients (Cohort 2). 
PhaseOut DMD (this open label Phase 2 trial) will include both the original formulation 
(F3) and the new formulation (F6) each with a modified diet. Each formulation is likely 
to exhibit different plasma concentration ranges which together with safety and 
pharmacodynamic data will aid in the selection of the preferred formulation and dose for 
future studies. By using both the F3 and F6 formulation in this study and allowing all 
patients with DMD irrespective of their SMT C1100 exposure levels to participate in this 
study, a wide concentration response range can be investigated, which will help to 
identify the range of SMT C1100 plasma levels that may modulate utrophin muscle 
levels sufficiently to provide therapeutic benefit. This will facilitate the design of future 
studies. 

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 14 of 89
CONFIDENTIAL
There has been an emphasis on developing objective non-invasive markers that can be used
as predictors of DMD disease severity and disease progression. The understanding of 
these biomarkers and their utility is still evolving but it is known that over the course of 
DMD, skeletal muscle is progressively replaced by fat and fibrosis, which can be 
measured by changes in magnetic resonance imaging (MRI). Magnetic resonance 
imaging measurements of inflammation and muscle adiposity are being investigated in this 
study as they are more objective and reproducible than measurements of muscle strength,
and are less influenced by patient effort or examiner variability.  
The average life-span of patients with DMD is 25–30 years [Merlini et al, 2015].
Currently there is no cure and only two approved treatments (one in the UK and one in the 
US) for a subset of ambulant boys with specific dystrophin gene mutations. The aim of 
SMT C1100 is to prevent continued muscle deterioration in boys with DMD by 
modulation of utrophin. As SMT C1100 is, theoretically, more likely to benefit those 
boys with adequate muscle mass and who are ambulatory, it is appropriate in this situation 
WRHQUROD\RXQJWR\HDUVPDOHSRSXODWLRQDVSDWLHQWVZLWK'0'XVXDOO\EHFRPH
wheelchair bound between the ages of 8–12 years. However, it is also important to gather 
long term safety data and data on other exploratory endpoints which might be relevant for 
an older and less ambulant patient population. The Sponsor aims to fulfil these obligations 
by enrolling boys who have taken part in prior SMTC1100 studies and who now most 
likely do not meet the age and functional criteria of the original PhaseOut DMD study 
(i.e., Cohorts 1 and 2). These patients will be enrolled in Cohort 3.  
Following completion of the 48 weeks of study patients in all three cohorts will be eligible 
to be rolled into the Extension Phase, which will continue until either SMT C1100 is 
approved in the relevant countries or development of SMT C1100 is discontinued and will 
provide additional safety and efficacy data. Entry into this phase of the study will be 
optional; patients and their parents/guardians must give additional assent/consent.
Objectives 
All objectives apply to all cohorts unless otherwise specified. 
Primary Objectives
x
To investigate changes in leg MRI in paediatric patients with DMD, 
following treatment with SMT C1100 (Cohorts 1 and 2) 
x
To investigate the relationships between changes in leg MRI with plasma 
concentrations of SMT C1100 and its metabolites in paediatric patients with 
DMD, following treatment with SMT C1100 (Cohorts 1 and 2) 
x
To assess the safety and tolerability of SMT C1100 and its metabolites in 
paediatric patients with DMD

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 15 of 89
CONFIDENTIAL
Secondary Objectives
x
To investigate changes in utrophin expression and muscle fibre regeneration in 
muscle, in paediatric patients with DMD, following treatment with SMT 
C1100 (Cohorts 1 and 2) 
x
To investigate the relationships between changes in utrophin expression and fibre 
regeneration in muscle and safety parameters with plasma concentrations of SMT 
C1100 and its metabolites in paediatric patients with DMD, following treatment 
with SMT C1100 (Cohorts 1 and 2) 
x
To investigate changes in pulmonary function tests in paediatric subjects with 
DMD, following treatment with SMT C1100 
x
To investigate the relationships between changes in pulmonary function tests with 
plasma concentrations of SMT C1100 and its metabolites in paediatric subjects 
with DMD, following treatment with SMT C1100 
Exploratory Objectives 
x
To investigate changes in functional measures, in paediatric patients with DMD, 
following treatment with SMT C1100, including the relationship between functional 
measures and exposure 
x
To investigate changes in paediatric outcomes data collection instrument (PODCI) 
scores in paediatric patients with DMD, following treatment with SMT C1100, 
including the relationship between PODCI scores and exposure  
x
To investigate changes in blood biomarkers in paediatric patients with DMD, 
following treatment with SMT C1100, including the relationship between blood 
biomarkers and exposure 
x
To investigate changes in cardiac MRI tests in paediatric subjects with DMD, 
following treatment with SMT C1100 (Cohort 3) 
x
To investigate the relationships between changes in cardiac MRI with plasma 
concentrations of SMT C1100 and its metabolites in paediatric subjects with DMD, 
following treatment with SMT C1100 (Cohort 3) 
Endpoints 
All endpoints apply to all cohorts unless otherwise specified. 
Primary Endpoints
x
Change from baseline to Weeks 12, 24, 36 and 48 in MRI leg muscle parameters 
(Cohorts 1 and 2)  
x
SMT C1100 and metabolite plasma concentrations at Weeks 1 (Days 1 and 7, as 
applicable (Cohorts 2 and 3 only)), 4, 8 (Cohorts 1 and 2 only), 12, 24, 36 and 48  

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 16 of 89
CONFIDENTIAL
x
Safety data including:
x
Treatment emergent AEs
Secondary Endpoints 
x
Change from baseline to Week 24 or 48 in utrophin expression via muscle biopsy 
analysis (Cohorts 1 and 2) 
x
Change from baseline to Week 24 or 48 in muscle regeneration biomarkers via 
muscle biopsy analysis (Cohorts 1 and 2) 
x
Change from baseline to Weeks 12, 24, 36 and 48 (Cohorts 1 and 2) and from 
baseline to Weeks 1, 24 and 48 (Cohort 3) in pulmonary function tests 
x
Safety data including:
x
Vital signs (systolic and diastolic blood pressure and heart rate) 
x
Physical examination
x
Twelve-lead electrocardiogram (ECG)
x
Echocardiogram (ECHO) 
x
Pulmonary function tests: 
x
Forced expiratory volume in 1 second (FEV1) 
x
Forced vital capacity (FVC) 
x
Maximum inspiratory pressure (MIP)  
x
Maximum expiratory pressure (MEP) 
x
Peak expiratory flow (PEF)
x
Peak cough flow (PCF) (Cohort 3) 
x
Sniff nasal inspiratory pressure (SNIP) (Cohort 3) 
x
Safety laboratory evaluations (clinical chemistry, haematology, (all 3 Cohorts) 
coagulation (Cohort 2 and Cohort 3) parameters and urinalysis (all 3 Cohorts)) 
Exploratory Endpoints 
x
Change from baseline to Week 12, 24, 36 and 48 for Cohorts 1 and 2 and from 
baseline to Week 24 and 48 for Cohort 3 (in the main phase of the study) measured 
at 6-monthly intervals for the duration of the Extension Phase in 6MWD 
x
Change from baseline to Week 12, 24, 36 and 48 for Cohorts 1 and 2 and from 
baseline to Week 24 and 48 for Cohort 3 (in the main phase of the study) and change 
measured at 6-monthly intervals for the duration of the Extension Phase in North 
Star Ambulatory Assessment (NSAA) global score

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 17 of 89
CONFIDENTIAL
x
Change from baseline to Week 12, 24, 36 and 48 (in the main phase of the study) 
measured at 6-monthly intervals for the duration of the Extension Phase in timed 
function tests (10 meter run/walk, time to stand) 
x
Change from baseline to Week 12, 24, 36 and 48 for Cohorts 1 and 2 and from 
baseline to Week 24 and 48 for Cohort 3 (in the main phase of the study) measured 
at 6-monthly intervals for the duration of the Extension Phase in paediatric outcomes 
data collection instrument (PODCI) scores
x
Change from baseline to Week 12, 24, 36 and 48 for Cohorts 1 and 2 and from 
baseline to Week 24 and 48 for Cohort 3 (in the main phase of the study) measured 
at 6-monthly intervals for the duration of the Extension Phase in Performance of 
Upper Limbs (PUL) 
x
Change from baseline to Week 12, 24, 36 and 48 (in the main phase of the study) and 
measured at 6-monthly intervals for the duration of the Extension Phase of blood 
biomarkers, e.g., creatine kinase, matrix metallopeptidase 9 and other biomarkers 
x
Change from baseline to Week 48 (in the main phase of the study) and measured at 
12-monthly intervals for the duration of the Extension Phase in cardiac MRI 
parameters (Cohort 3) 
x
Change from baseline in MRI leg muscle parameters measured at 6-monthly 
intervals for the duration of the Extension Phase (Cohorts 1 and 2)  
x
SMT C1100 and metabolite plasma concentrations measured at 6-monthly intervals 
for the duration of the Extension Phase 
x
Change from baseline in pulmonary function tests measured at 6-monthly intervals 
for the duration of the Extension Phase 
It should be noted that patients in Cohort 3 may not be able to perform all of the 
functional tests at baseline. Therefore the patients included in the analyses for these tests 
will be test specific and based upon their baseline ability to perform the test.
Study Design 
This is a Phase 2, open-label study to assess the activity and safety of utrophin 
modulation with SMT C1100 administered orally bid in ambulatory paediatric male 
patients with DMD. In Cohort 1, approximately 30 patients with DMD will be 
administered 2.5 g bid of SMT C1100 F3. In Cohort 2, approximately 10 patients will be 
administered 1 g bid of SMT C1100 F6. In Cohort 3, approximately 15 patients, who 
have previously received SMT C1100, but who are not eligible for Cohorts 1 or 2, will be 
administered 2.5 g bid of SMT C1100 F3.  
Cohort 1, in which F3 will be investigated, will be conducted in a multi-centre setting in 
both United Kingdom (UK) and the United States of America (USA). Cohort 2, in which 
F6 will be investigated, will only be conducted at specific centres in the USA. Cohort 3 
will only be conducted in the UK and will use the F3 formulation. All cohorts have a 

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 18 of 89
CONFIDENTIAL
Screening and Baseline Phase of up to 28 days, an open label Treatment Phase and a 30-
day Safety Follow up Phase. 
During the Treatment Phase, patients will be dosed by their parents/responsible-adult 
twice-daily with approximately 8–12 hours between breakfast and evening meal doses.  
Following completion of the initial 48-weeks of the open label Treatment Phase, patients 
will be eligible to consider receiving SMT C1100 until either SMT C1100 is approved in 
the relevant countries or development of SMT C1100 is discontinued. All patients will 
receive the same formulation as they had previously been receiving, twice-daily.
Study Population 
Forty PDOHSDWLHQWVDJHGWR\HDUVLQFOXVLYHZLWKDGLDJQRVLVRI'0'FRQILUPHG
by phenotypic and genetic evidence) who are willing to assent and whose 
parents/guardian consent and agree to undergo two muscle biopsies will be enrolled in 
either Cohort 1 or Cohort 2 of the study. Patients in Cohorts 1 and 2 must be <10 years 
old, able to walk 300 metres, have a consistent 6MWD (second reading within 20% of 
the first) and have a cardiac ECHO showing an ejection fraction of >55% and a fractional 
shortening of >28%. 
Approximately 15 male patients with a diagnosis of DMD (confirmed by phenotypic and 
genetic evidence) who have previously received SMT C1100, but who are not eligible for 
Cohorts 1 or 2, who are willing to assent and whose parents/guardian consent will be 
enrolled in Cohort 3. 
All patients who have completed the initial 48-week Treatment Phase will be eligible to 
continue into the Extension Phase which will last until SMT C1100 is approved in the 
relevant countries or development of SMT C1100 is discontinued. 

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 19 of 89
CONFIDENTIAL
Study Assessments
Time and Events Table 
Cohorts 1 and 2 ONLY
Phase
Screening 
Phase
Baseline 
Phase
Treatment Phase – Cohorts 1 and 2
Early 
termination 
visit
End of 
study 
visit
Day(D)/Week(W)
up to D-28 to D-1
W1/
Day 1
W1/
Day 7l,o 
W4
+ 1 wo 
W8
+ 1 wo 
W12
+/-2 w
W24
+/-2 w
W36
+/-2 w
W48
+/-2 w
W52 
+/- 2 w
Informed consent and assent
X
Resident at site 
X
X
X
X
Demographic data
X
Medical history
X
Inclusion/exclusion criteria
X
Nutritionist appointment
X
Vital signs
X
X
X
X
X
X
X
X
X
Physical examination
X
X
X
X
X
X
X
X
12-lead electrocardiogram
X
X
Xh
Xg
Xh
Xg
Xh
X
X
Echocardiogram 
X
X
X
X a
X
Pulmonary assessments b
X
X
X
X
X
X a
X
Haematology, clinical chemistry and 
urinalysis 
X
Xc
X
X
X
X
X
X
Coagulation testsl
X
Xc
X
X
X
X
X
X
X
Liver function tests, including glutamate 
dehydrogenase; amylase and lipase
X
X
X
Xl
X
X
X
X
X
X
X
X
C4 and FGF19
X
Xj
Xj
Xj
X
MRI - leg
X
X
X
X
X
X d
NSAA
X
X
X
X
X
X
X
10 metre run/walk
X
X
X
X
X
X
X
Six minute walk distance/test
X
X
X
X
X
X
X
X
Muscle Biopsy e
X
X
X
X
PODCI
X
X
X
X
X
X
X
PUL n
X
X
X
X
X
X
X
Blood biomarkers f
X
Xf
X
X
X
X
X
X
X
X

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 20 of 89
CONFIDENTIAL
Phase
Screening 
Phase
Baseline 
Phase
Treatment Phase – Cohorts 1 and 2
Early 
termination 
visit
End of 
study 
visit
Day(D)/Week(W)
up to D-28 to D-1
W1/
Day 1
W1/
Day 7l,o 
W4
+ 1 wo 
W8
+ 1 wo 
W12
+/-2 w
W24
+/-2 w
W36
+/-2 w
W48
+/-2 w
W52 
+/- 2 w
SMT C1100 parent and metabolites 
pharmacokinetic sampling
Xi
Xl,m
Xk
Xi
Xi
Xk
Xi
Xk
X
X
SMT C1100 bid dosing
X
X
X
X
X
X
X
X
Adverse event recording
X
X
X
X
X
X
X
X
X
X
X
X
Prior and concomitant medications
X
X
X
X
X
X
X
X
X
X
X
X
If multiple assessments are at the same time point, it is appreciated that some deviation in timing will be necessary. A ±15 minute window is acceptable with pharmacokinetic 
samples being performed as close to scheduled time point as possible. Please see the study manual for more information on timing.
a.
If not performed in the last 12 weeks. 
b.
Pulmonary assessments include forced expiratory volume in 1 second, peak expiratory flow, forced vital capacity, maximum inspiratory pressure and maximum expiratory 
pressure
c.
These need not be repeated at Day -1 if they have been performed within 7 days of Day 1. All samples should be collected in a fasting condition
d.
If not performed in the last 6 weeks.
e.
A maximum of two muscle biopsies will be taken one of which will be at baseline. The patients will be assigned as to when they will receive the second muscle biopsy procedure. 
The first 8 patients in Cohort 1 will have a biopsy at 24 weeks and the remaining 22 patients will be alternately assigned between the 24 week and the 48 week time points. The 
first 6 patients in Cohort 2 will have a biopsy at 24 weeks and the remaining 4 patients will have theirs at the 48 week time point. If the patient has not performed their second 
biopsy prior to their early termination from the study, at the Sponsor’s discretion, it may be performed at their Early Termination visit. 
f.
Plasma biomarkers include creatine kinase, matrix metalloproteinase 9, and others, as well as quantification of changes of proteins. Note: creatinine kinase and MMP-9 will not 
be collected at Week 1.
g.
ECG to be performed 4 hours post AM dose.
h.
ECGs to be performed pre-AM dose and 0.5, 2, 4 and 6 h post-AM dose OR pre-PM dose and 0.5, 2 and 4 h post-PM dose.
i.
Each patient will have three PK samples taken at pre-AM dose and, 3 and 6 h post-AM dose 
j.
Samples to be collected pre-AM dose, 3 h post- AM dose, pre-PM dose and 4 h post-PM dose; At Week 1, only AM samples apply
k.
Each patient will have three PK samples taken at pre-PM dose and 4 and 10 h (+ up to 4 hours but before the next AM dose) after the PM dose. 
l.
Cohort 2 only.  
m.
One PK sample collected at 4 hours post-AM dose.
n.
Where a biopsy is performed at the same visit this procedure should be performed prior to the biopsy.
o.
Laboratory assessments may be conducted by the sponsor-provided home nursing vendor on Day 7 (Cohort 2 only) and Weeks 4 and 8 (Cohorts 1 and 2).

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 21 of 89
CONFIDENTIAL
Time and Events Table 
Cohort 3 ONLY
Screening
Phase
Treatment Phase
Cohort 3
Early
termination
visit
End of
study visit
D-28 to D-
1
W1/Day 1
W1/Day 7i
W4 + 1i w 
W12 +/-2 w 
W24 +/-2 w 
W36 +/-2 w 
W48 +/-2 w 
W52 +/- 2 w 
Informed consent and assent
X
Demographic data
X
Medical history
X
Inclusion/exclusioncriteria
X
Nutritionistappointment
X
Vital signs
X
X
X
X
X
X
X
X
Physical examination
X
X
X
X
X
X
X
12-leadelectrocardiogram 
X
Xd
Xd
Xd
Xd
X
X
Cardiac magnetic resonance 
imaging
X
X
Xg
Pulmonary assessments a
X
X
X
X
X
X
X
Haematology, coagulation, 
clinical chemistry &urinalysis
X
X
X
X
X
X
X
X
X
Liver function tests, including
glutamate dehydrogenase;
amylase and lipase
X
X
X
X
X
X
X
X
X
C4 and FGF19
X
Xf
Xf
X
NSAA
X
X
X
X
X
10 metre run/walk
X
X
X
X
X
Six minute walk distance/test
X
X
X
X
X
PODCI
X
X
X
X
X
PULb
X
X
X
X
X
Blood biomarker separate 
sample c
X
X
X
X
X
X
X

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 22 of 89
CONFIDENTIAL
Screening
Phase
Treatment Phase
Cohort 3
Early
termination
visit
End of
study visit
D-28 to D-
1
W1/Day 1
W1/Day 7i
W4 + 1i w 
W12 +/-2 w 
W24 +/-2 w 
W36 +/-2 w 
W48 +/-2 w 
W52 +/- 2 w 
SMTC1100 parent &
metabolites sparse 
pharmacokinetic
samplinge 
X
Xh
X
X
X
X
X
X
X
SMT C1100 bid dosing
X
X
X
X
X
X
X
Adverse event recording
X
X
X
X
X
X
X
X
X
X
Prior and concomitant
medications
X
X
X
X
X
X
X
X
X
X
If multiple assessments are at the same time point, it is appreciated that some deviation in timing will be necessary. A ±15 minute window is acceptable with pharmacokinetic 
samples being performed as close to scheduled time point as possible. Please see the study manual for more information on timing.
a.
Pulmonary assessments include forced expiratory volume in 1 second, peak expiratory flow, forced vital capacity, maximum inspiratory pressure, maximum expiratory pressure, 
peak cough flow and sniff nasal inspiratory pressure.
b.
Where a biopsy is performed at the same visit this procedure should be performed prior to the biopsy.
c.
Plasma biomarkers include creatine kinase, matrix metalloproteinase 9, and others, as well as quantification of changes of proteins. Note: creatinine kinase and MMP-9 will not 
be collected at Week 1.
d.
ECGs to be performed pre-AM dose and 0.5, 2, 4 and 6 h post-AM dose 
e.
Each patient will have three PK samples taken at pre-AM dose and, 3 and 6 h post-AM dose 
f.
Samples to be collected pre-AM dose, 3 h post- AM dose, pre-PM dose and 4 h post-PM dose; At Week 1, only AM samples apply
g.
If not performed in the last 6 weeks.
h.
One PK sample collected at 4 h post-am dose.
i.
Laboratory assessments may be conducted by the sponsor-provided home nursing vendor on Day 7 and Week 4.

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 23 of 89
CONFIDENTIAL
Time and Events Table 
Extension phase
Entry
Phase/ 
Baseline Phase
Treatment Phase
Cohorts 1, 2 and 3
To be repeated at the time points below in each 
year of the treatment phase until either SMT C1100 
is approved in the relevant countries or 
development of SMT C1100 is discontinued.
Early termination visit
Approval/ 
Discontinuation
W48 of original 
Phase Out DMDh 
12 W
+/-2 wg 
24 W
+/-2 w
36 W
+/-2 wg
48 W 
+/- 2 w
Approval +/- 2 w
Informed consent and assent
X
Vital signs
X
X
X
X
X
X
X
Physical examination
X
X
X
X
X
12-lead electrocardiogram
X a
Xb
Xb
Xb
Xb
Echocardiogram 
X
Xi
Xi
X
X
Pulmonary assessments c
X
X
X
X
X
Haematology, clinical chemistry, coagulation 
parameters f, and urinalysis
X
X
X
X
X
X
X
Liver function tests, including glutamate, 
dehydrogenase, amylase, and lipase
X
X
X
X
X
X 
X 
Leg MRI 
(Cohort 1 and 2 only)
X
X
X
X
Cardiac MRI 
(Cohort 3 only)
X
X
X
NSAA
X
X
X
X
X
10 metre run/walk,
X
X
X
X
X
Six minute walk distance/test
X
X
X
X
X
PODCI, EQ-5D,UL- PROM, 
X
X
X
X
X
PUL 
X
X
X
X
X
Blood biomarkers d,
X
X
X
X
X
SMT C1100 parent and metabolites PK
X
Xe
Xe
X
X
SMT C1100 bid dosing
X
X
X
X
X
Adverse event recording
X
X
X
X
X
X
X
Concomitant medications
X
X
X
X
X
X
X

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 24 of 89
CONFIDENTIAL
If multiple assessments are at the same time point, it is appreciated that some deviation in timing will be necessary. A ±15 minute window is acceptable with pharmacokinetic samples 
being performed as close to scheduled time point as possible. Please see the study manual for more information on timing.
a.
ECG at 0.5,2,4 and 6 h after am dose
b.
ECG at a single time point 4 hours after dosing
c.
Pulmonary assessments include forced expiratory volume in 1 second, peak expiratory flow, forced vital capacity, maximum inspiratory pressure and maximum expiratory 
pressure
d.
Plasma biomarkers include creatine kinase, matrix metalloproteinase 9, and others, as well as quantification of changes of proteins. Note: creatine kinase and MMP-9 will not be 
collected at Week 1.
e.
Each patient will have single PK samples taken at 4 h post-AM dose 
f.
Coagulation parameters for Cohort 2 and Cohort 3 only.  
g.
If only the procedures in this column are being performed at a visit then the visit may be performed at the study site or samples may be collected by the study appointed home 
nursing vendor with AE and concomitant medication checks being performed in a documented telephone call.
h.
The Week 48 visit of PhaseOut DMD is counted as the baseline visit for the extension phase. These procedures do not need to be repeated.

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 25 of 89
CONFIDENTIAL
1.
INTRODUCTION
1.1. 
Background 
Duchenne muscular dystrophy (DMD) is a progressive, lethal muscle wasting disease 
characterised by a generalised weakness and progressive loss of muscle strength; 
ultimately, cardiac and respiratory difficulties present, leading to death [Mercuri et al,
2013]. Duchenne muscular dystrophy is an X-linked recessive disorder with a global 
estimated incidence of approximately 1 in 3500 live male births caused by mutations or 
deletions in the dystrophin gene [Mammen et al, 2015]. Dystrophin provides a link 
between the actin cytoskeleton and the dystrophin protein complex group of proteins that 
are anchored in the cell membrane so enabling stabilisation of the membrane during 
contraction and relaxation [Cirak et al, 2012]. A lack of functional dystrophin results in 
structural and functional changes in muscle fibres, whereby repeated cycles of muscle 
necrosis and regeneration lead to the eventual replacement of muscle by adipose and 
connective tissue. Currently there is no effective treatment for DMD [Kharra et al, 2014]. 
Various strategies developed to alleviate the symptoms include steroid treatment [Ricotti
et al, 2013], anti-inflammatory agents [Serra et al, 2012], and growth hormone and 
myostatin inhibitors [Zatz et al, 1986; Bogdanovich et al, 2002]. More recently, the 
majority of nonclinical and clinical investigational studies have examined gene therapy 
approaches, that focus on restoring the deficient dystrophin in the muscle fibres [Bowles
et al, 2012; Falzaranoet al, 2014]. 
The potential for utrophin to act as a functional replacement for dystrophin has been 
recognised for some time [Sonnemann et al, 2009]. The utrophin gene is the autosomal 
homologue of dystrophin and utrophin and dystrophin share similar structural 
organisational motifs and binding properties. Summit is developing SMT C1100, which 
is the first in a new pharmacological class of small molecules that act to increase 
transcription of utrophin. Summit has demonstrated that SMT C1100 increases levels of 
utrophin ribonucleic acid (RNA) and protein in human and mouse cells. This increase in 
utrophin protein has been shown in dystrophin-deficient muscle cells taken from DMD 
patients and confirmed in vivo in a mouse model (mdx) [Tinsley et al, 2011]. 
The mdx mouse is a genetic surrogate of the human DMD condition although it presents 
with a relatively mild histopathological and clinical phenotype. Summit showed that 
SMT C1100 dosed to mdx mice at 50 mg/kg/day reduced a number of the pathological 
effects of dystrophin deficiency [Tinsley et al. 2011]. Treatment resulted in reduced 
muscle pathology (regeneration, fibrosis, inflammation), better muscle physiology 
(leading to an increase in overall strength) and an ability to resist fatigue after forced 
exercise. The significant clinical advantage of utrophin modulation over other approaches 
is that the therapy may be beneficial to all DMD patients, regardless of the type of 
dystrophin mutation. 

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 26 of 89
CONFIDENTIAL
SMT C1100 has been shown to be safe and well tolerated in the following studies: 
nonclinical toxicology studies up to 39 weeks of treatment in three species; a Phase 1 
study in healthy volunteers for up to 10 days of treatment with 0.2 g/kg bis in die (bid)
[Tinsley et al, 2015] and 3 studies with DMD paediatric patients. 
Study SMT C11002 was an open-label, non-randomised, Phase 1 study consisting of 
three groups of DMD paediatric patients. Each group received SMT C1100 for up to 
11 days treatment, with doses up to 0.1 g/kg ter in die (tid) with a microfluidised 
formulation (F2). 
In study SMT C11003 (a Phase 1b placebo-controlled study) patients with DMD 
completed three 14-Day dosing periods during which they received SMT C1100 (F3) 
1.25 g bid, SMT C1100 (F3) 2.5 g bid and placebo bid in a cross-over dose ascending 
manner. Single and multiple oral doses of 1.25 g and 2.5 g bid were safe and well 
tolerated in these paediatric DMD patients. A balanced diet improved the bioavailability 
of SMT C1100 (F3), particularly after the evening 2.5 g dose. As before the 
pharmacokinetics of SMT C1100 (F3) were characterised by prolonged absorption and 
high between-patient variability in systemic exposure, and evidence of diurnal variation.  
Study SMT C11004 was an open-label, non-randomised, Phase 1 study consisting of two 
parts. Part A, a single-centre study in healthy adult male subjects and Part B a multicenter 
study in male paediatric patients with DMD, conducted at five centres in the United 
Kingdom. In Part A SMT C1100 was given as an oral nanosuspension (F5) and a powder 
for oral suspension (F6). In healthy adults, exposures of SMT C1100 were higher when 
SMT C1100 was dosed as F6 formulation compared to the F5 formulation. For instance, 
comparing the exposures obtained at the end of the dosing period (Day 5 [PM]); the 
exposure with the 4 g bid F6 formulation (2279 ng/mL and 10890 ng*h/mL for Cmax and 
AUC, respectively) compared to 6 g bid with the nanosuspension (371.5 ng/mL and 2844 
ng*h/mL for Cmax and AUC, respectively), were 9.2 and 5.7-fold higher on a dose 
normalized basis for Cmax and AUC, respectively.  In Part B, F6 was given to each patient 
for 7 days in each of three treatment periods, with escalating doses (0.25g, 0.5g and 1g) 
of F6 administered bid. There was a minimum of a 7 day washout period between each 
treatment period.  
In Study SMT C11004 SMT C1100 was generally well tolerated with only one serious 
adverse event (SAE) being reported (high liver function tests (primarily elevated 
conjugated bilirubin) in a patient with DMD). Due to this SAE, patients will undergo 
additional monitoring for liver abnormalities in this study.
The PhaseOut DMD study involving a second cohort of patients dosed with F6 aims to 
provide further information on the safety and pharmacokinetics of the F6 formulation, 
and corresponding higher SMT C1100 exposure, over a longer time period. 

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 27 of 89
CONFIDENTIAL
1.1.1.
Name and Description of the Investigational Medicinal Product
The investigational medicinal product (IMP) used in Cohort 1 and Cohort 3 of this study 
is an oral microfluidised aqueous suspension of SMT C1100, 5-(ethylsulfonyl)-2-
(naphthalen-2-yl)benzo[d]oxazole (also known as formulation F3). 
The IMP used in Cohort 2 of this study is a powder for oral suspension of SMT C1100, 
5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole (also known as formulation F6). 


Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 28 of 89
CONFIDENTIAL



Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 29 of 89
CONFIDENTIAL
  

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 30 of 89
CONFIDENTIAL




Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 31 of 89
CONFIDENTIAL
  




  




1.1.3.
Summary of Clinical Studies in the Duchenne Muscular 
Dystrophy Population
In an open-label Phase 1b study (SMT C11002), SMT C1100 was administered orally as 
a microfluidised aqueous suspension (F2) to assess the safety, tolerability and 
pharmacokinetics of single and multiple doses in paediatric patients with DMD. Group 
A’s treatment consisted of oral doses of SMT C1100 0.05 g/kg given once on Day 1, bid
on Days 2–10 and once on Day 11. Group B’s treatment consisted of oral doses of SMT 
C1100 0.1 g/kg given once on Day 1, bid on Days 2–10, and once on Day 11. Group C’s 

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 32 of 89
CONFIDENTIAL
treatment consisted of oral doses of SMT C1100 0.1 g/kg given once on Day 1, tid on 
Days 2–10, and once on Day 11. Overall, multiple doses of SMT C1100 were safe and 
well tolerated at dose levels up to 0.1 g/kg tid, with the most frequent adverse event (AE) 
being pale stools. Patients in SMT C11002 were requested to take their doses within 
10 minutes of food; however, there was no standardisation of meals consumed prior to 
dosing. It was therefore unknown what contribution the differences in food intake prior to 
dosing had on the extent of SMT C1100 exposure and between-patient variability.
Following single and multiple oral administrations, SMT C1100 was rapidly absorbed 
with time of maximum concentration (tmax) being attained within approximately 1–
6 hours in all patients. SMT C1100 exhibited biphasic elimination with an apparent dose-
independent terminal elimination half-life (t1/2), with mean t1/2 ranging from 
approximately 5–10 hours. Similarly to results seen in study SMT C11001 (conducted in 
healthy adults), single and multiple oral dose pharmacokinetics of SMT C1100 in male 
paediatric patients with DMD demonstrated large variability between patients and 
provided no evidence that increasing dose or differing dosing regimen had an impact on 
exposure. There was high between-patient variability (geometric coefficient of variation 
of 78–248%) in AUC(0–tlast), area under the concentration curve from time 0 to the time of 
next dose (AUC(0–tau)) and Cmax. The comparison of doses and regimens was hindered by 
this large variability and the presence of only four patients per group. Observed 
exposures were lower than anticipated with only a single patient receiving bid dosing 
achieving target exposures. Following 11 days of bid dosing, SMT C1100 exposure was 
significantly reduced, with systemic exposure (assessed by AUC(0–tau)) being 
approximately 56–65% lower on Day 11 compared to Day 1. A time-dependent reduction 
in exposure was observed in study SMT C11001, albeit not to the same magnitude (23–
40% reduction) suggesting that SMT C1100 is subject to autoinduction, although  AhR-
mediated induction of CYP1A was not evident from in vitro evaluation. 
In Study SMT C11002, the pharmacokinetic analysis of metabolites DHD I and DHD III 
obtained from an exploratory assay, revealed broadly similar disposition (tmax and t1/2) to 
that of the parent drug. Both metabolites were markedly more abundant than SMT C1100 
in plasma, with mean metabolite ratios appearing to be independent of dose. On Day 1, 
mean metabolite ratios ranged from 10.8–36.0 and 20.6–58.5 for DHD I and DHD III, 
respectively. Following multiple dosing, metabolite ratios were higher, ranging from 
46.6–74.2 and 63.2–112 for DHD I and DHD III, respectively. As the exposure of DHD I 
and DHD III at 0.1 g/kg bid and tid doses was similar between Days 1 and 11, these data 
indicate that the increase in metabolite ratios are a reflection of a reduction in exposure to 
SMT C1100 over time. 
Although DHD I levels in Study SMT C11002 were within the levels seen in the animal 
toxicology studies, the DHD III levels for some patients exceeded those seen in the 
female rat toxicology study. However, a battery of in vitro assessments did not identify 

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 33 of 89
CONFIDENTIAL
any unique safety concern for DHD III relative to SMT C1100 or DHD I and there were 
no adverse effects in patients that might be related to any of the off-target effects 
identified in vitro for SMT C1100, DHD I or DHD III.
Study SMT C11003 was a Phase 1b placebo-controlled, multi-centre, randomised, 
double-blind dose escalation study to evaluate the pharmacokinetics and safety of SMT 
C1100 in patients with DMD who were following a balanced diet and consumed 100 mL 
full-fat (whole) milk immediately after dosing with F3. Twelve patients were enrolled in 
this study and patients completed three 14-Day dosing periods during which they 
received SMT C1100 1.25 g bid, SMT C1100 2.5 g bid and placebo bid in a cross-over 
dose ascending manner. 
Single and multiple oral doses of 1.25 g and 2.5 g bid were safe and well tolerated in 
paediatric DMD patients. A balanced diet improved the bioavailability of SMT C1100, 
particularly after the evening 2.5 g dose. As before the pharmacokinetics of SMT C1100 
were characterised by prolonged absorption and high between-patient variability in 
systemic exposure, and evidence of diurnal variation. Systemic exposure of DHD I and 
DHD III were markedly higher than that of SMT C1100, with no dose or time 
dependency in metabolite ratios.  
At both dose levels, there were no severe AEs, no study discontinuations due to an AE, 
and no serious AEs reported during the study. The majority of AEs were mild 
gastrointestinal disorders which resolved without treatment. The most frequently reported 
TEAE was pale stools and thus consistent with TEAEs in previous clinical studies. The 
only other drug-related TEAEs reported with SMT C1100 were diarrhoea, pain in the 
upper abdomen and constipation. The reporting of these TEAEs for patients administered 
active drug was similar to that reported during treatment with placebo.  
In the Investigator’s opinion there were no clinically important findings for clinical 
laboratory evaluations, vital signs, 12-lead ECGs, or physical examinations performed 
during the study. 
SMT C11004 was an open-label, nonrandomised, Phase 1 study consisting of two parts. 
Part A was a single-centre study in healthy adult male subjects where 2 formulations of 
SMT C1100 were investigated (an oral nanosuspension (F5) and a powder for oral 
suspension (F6)). Part B was a multicenter study in male paediatric patients with DMD 
conducted at five centres in the United Kingdom where only the F6 formulation was 
investigated.  
In Part A, one subject who received SMT C1100 F6 formulation at 4 g bid discontinued 
due to a TEAE of upper abdominal pain that was considered related to study drug by the 
investigator. All 16 subjects reported TEAEs, the majority of which were mild. 
‘Discoloured faeces’ was the most frequently-reported TEAE. Headache and nausea were 

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 34 of 89
CONFIDENTIAL
the other drug-related TEAEs reported with the nanosuspension and Change of Bowel 
Habit, Abdominal Discomfort, Faeces Pale, Abdominal Pain, Diarrhoea, Dyspepsia and 
Nausea reported for the powder for oral suspension formulation. Transient increases in 
liver-related laboratory tests were observed during the dosing period, though no subject 
satisfied any of Hy’s criteria and values returned to baseline after dosing had stopped. 
In Part B seven of the eight patients experienced at least one TEAE with all but one event 
being considered mild or moderate by the Investigator. There was one SAE of elevated 
liver function test abnormalities with the 0.25 g bid, dose, the cause of which is unknown. 
The patient himself was clinically well but nevertheless discontinued from the study after 
a positive rechallenge in Period 2. Laboratory values for this patient returned to the 
normal range at the 2-week follow up. One additional patient discontinued on Day 7 after 
his AM dose in the 1 g bid dose period for an AE of abdominal pain. The majority of the
AEs were gastrointestinal in nature with diarrhoea being the most frequently reported 
event; interestingly, pale faeces were reported only during dosing with 0.5 g bid. 
With respect to the pharmacokinetic profile with DMD patients, overall there was an 
increase in steady state Cmax and AUC0–24 with increasing dose which was greater than 
dose proportional with the two higher dose levels (0.5 and 1g bid), however there was 
little to no accumulation with repeated dosing. There was dose proportionality between 
the 0.25 g bid and 0.5 g bid dose levels. At the two highest dose levels mean (geometric) 
Cmax was above levels that in vitro increased utrophin production, with the highest 
geometric mean Cmax over 24 hours being 390 ng/mL at the 1 g bid dose level, at steady 
state. 
Further information can be found in the Investigator’s Brochure [Investigator’s Brochure
2016] for SMT C1100. 
1.1.4.
Study Conduct
This study will be conducted in accordance with the requirements of this document (the 
Clinical Study Protocol), the Study Reference Manual and also in accordance with the 
following:  
x
Declaration of Helsinki (revised version of Fortaleza, Brazil, 2013)
x
The International Council on Harmonization harmonized tripartite guideline 
regarding Good Clinical Practice (ICH-GCP; E6 (R2) Consolidated Guidance, 
November 2016) 
x
Local laws and regulations 
x
Any amendments to these regulations  

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 35 of 89
CONFIDENTIAL
1.2. 
Rationale 
This open-label study (SMT C11005) will be the first Phase 2 study of a utrophin 
modulator in boys with DMD.
The decision to progress into clinical development was taken after SMT C1100 
demonstrated significant disease-modifying potential for DMD in non-clinical efficacy
studies. SMT C1100 has been shown to increase utrophin RNA and protein and reduce 
muscle damage, in vivo, in the mdx mouse model of DMD disease [Tinsley et al, 2011]. 
In vitro assays with human myotubes or human DMD cells treated with SMT C1100 
demonstrated a 25% increase in utrophin messenger RNA and a 100% increase in
utrophin protein, respectively, leading to an estimated EC50 of 0.2 micromolar (67 ng/mL)
in the in vitro myotube assay and an EC50 level of 33.7 ng/mL in the in vitro DMD
myoblast assay.
A key question for all utrophin modulator studies relates to how much utrophin is
necessary to slow down the muscle degeneration of DMD boys. There is likely to be a 
level of protein that is sufficient to maintain proper membrane organisation and function, 
and prevent the degenerative process. However, lower levels of utrophin could slow down 
the rate of muscle fibre degeneration which would still be of significant benefit to DMD boys. 
The same question is being investigated for dystrophin. Godfrey et al have shown that a 
low (15% homogeneous dystrophin) expression is sufficient to protect against eccentric 
contraction-induced injury in mdx [Godfrey et al, 2015]. Strikingly, changes in muscle 
strength were proportional to dystrophin expression levels. These data appear to define 
the dystrophin restoration levels required to slow down or prevent disease progression 
and improve overall muscle function once a dystrophic environment has been established 
in the mdx mouse model. Analysis of dystrophin levels in Becker patients with 
dystrophin truncations, which mimic the protein the exon skipping drug hopes to create, 
suggests levels significantly lower than normal levels will provide significant benefit. 
One publication suggests that threshold rather than dose–effect relationship of dystrophin 
levels determines disease severity. This threshold could be around 10% of normal 
dystrophin levels (at least for the exon 45–47 deletion), which has important implications 
for therapeutic approaches that aim to restore dystrophin [Van den Bergen et al, 2014]. A 
second publication showed that dystrophin protein levels in Becker patients (who express 
the same internally deleted dystrophin as could be induced by exon skipping therapies) 
are mostly associated with mild phenotypes and that these patients express dystrophin at 
a high enough level (at least 40% of control) to provide a functional benefit [Anthony et 
al, 2011]. 
Previous studies with SMT C1100 have dosed for a maximum of 2 weeks whereas this study 
will involve initially dosing for 48 weeks, but potentially dosing for longer periods of time 
(until SMT C1100 is approved in the relevant countries or development of SMT C1100 is 

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 36 of 89
CONFIDENTIAL
discontinued). The primary objectives of this study are to evaluate changes in leg magnetic
resonance imaging (MRI) parameters over time as well as evaluate the efficacy and safety
of long term dosing with SMT C1100 in a larger population of boys with DMD. This 
study will investigate the relationship between the SMT C1100 pharmacokinetic levels 
and utrophin modulation and muscle markers of regeneration. It will also investigate 
whether a relationship exists between utrophin modulation and muscle markers of 
regeneration. Further, this open-label concentration-response study will also examine 
whether the potentially observed utrophin modulation does indeed lead to improvements 
in markers of muscle disease progression as indicated by the MRI fat fraction in leg 
muscles or in long term improvements in functional endpoints such as the six-minute 
walk distance (6MWD). Results of this study will enable the design of a pivotal study.  
Following completion of the 48 weeks of study, patients in all three cohorts will be 
eligible to be rolled into the Extension Phase, which will continue until either SMT C1100 
is approved in the relevant countries or development of SMT C1100 is discontinued, and 
will provide additional safety and efficacy data. Entry into this phase of the study will be 
optional; patients and their parents/guardians must give additional assent/consent. 
Currently there is no cure for all boys with DMD although two treatments (one in the US 
and one in EU) are available for subset of ambulant boys with specific dystrophin gene 
mutation. The average life- span of patients with DMD is 25–30 years [Merlini et al,
2015]. SMT C1100 aims to prevent continued muscle deterioration in boys with DMD. It 
is theoretically most likely to benefit those boys with adequate muscle mass and those who
are ambulatory. Thus it is appropriate to enrol a younger WRyears) DMD 
population in Cohorts 1 and 2 as patients usually become wheelchair bound between the 
ages of 8–12 years [Uzark et al, 2012]. However, based on the natural history data, we 
expect there will be patients who have taken part in prior SMT C1100 studies who now 
do not meet the entry criteria for Cohorts 1 and 2 and are most likely to be a risk for 
cardio-respiratory decline. These patients will be enrolled in this study in Cohort 3 and 
have cardiac and respiratory end points measured, providing essential data for the safety 
database and allowing the assessment of endpoints relevant in an advancing patient 
population. 
In a previously reported study of SMT C1100 in DMD patients (SMT C11002), results 
showed that SMT C1100 was safe and well tolerated at doses up to 0.1 g/kg tid as a 
microfluidised aqueous suspension (F2). However, patients had variable plasma
concentrations of SMT C1100 with only two of the patients achieving concentrations 
similar to those seen in a fed study with healthy adult volunteers (SMT C11001). 
Retrospective dietary data collection suggested that boys in SMT C11002 with DMD 
followed a low fat diet.

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 37 of 89
CONFIDENTIAL
Consequently it was hypothesised that SMT C1100 exposure could be improved by
dietary manipulation. In study SMT C11003, patients with DMD were requested to take
their doses with 100 mL full-fat milk and follow a balanced diet. The data from SMT
C11003 supported the hypothesis demonstrating improved exposure of SMT C1100. As 
discussed above, these concentrations have been shown, in vitro, in both human myotubes 
and DMD myoblasts, to upregulate utrophin. Patients who were involved in both the SMT 
C11002 and SMT C11003 studies showed increased exposure when they took 
SMT C1100 with milk in the SMT C11003 study compared to the SMT C11002 study 
where milk was not required to be consumed with SMT C1100. Results in Study SMT 
C11004 showed that the F6 formulation of SMT C1100 had significantly improved 
pharmacokinetic properties with higher Cmax and AUC’s achieved (greater than six-fold 
increase in maximum SMT C1100 plasma levels), and was safe and well tolerated at 
doses up to the maximum dose used, 1 g bid. Consequently this formulation and dose will 
also be investigated in a small number of patients in Study SMT C11005. 
By allowing all patients with DMD, irrespective of SMT C1100 levels, to participate in 
this study, we aim to address some of the questions about appropriate utrophin levels for 
benefit as even low plasma levels of SMT C1100 may modulate utrophin muscle levels 
enough to be of some clinical benefit.  
With the low SMT C1100 exposure partly mitigated by asking patients with DMD to
follow a balanced diet and consume 100 mL milk with SMT C1100 and with the 
development of formulation (F6), the next stage of SMT C1100 development is SMT 
C11005, a proof-of-concept study. 
In two different studies (SMT C11002 and SMT C11003), each of which enrolled 
12 patients, patients with DMD were exposed to SMT C1100 for between 11–14 days. 
Including SMT C11004 there is a total SMT C1100 exposure, in all previous studies, of 
615 dosing days in 22 individual boys with DMD. In contrast, should all patients 
complete the SMT C11005 study per protocol the total SMT C1100 exposure in days will 
be considerably greater (15,120 dosing days) increasing even further if all elect to 
continue in the Extension Phase. By measuring pharmacokinetic endpoints of SMT 
C1100, and its DHD metabolites, at different time points throughout the study Summit 
will examine the correlation between systemic exposure and longer term safety.
For this study leg MRI will be used in Cohorts 1 and 2 for monitoring disease progression 
after intervention with SMT C1100, by evaluating muscle fat infiltration and
inflammation. Both are considered markers of disease progression in patients with DMD.  
Magnetic resonance imaging measurements of inflammation and muscle adiposity are
more objective and reproducible than measurements of muscle strength and are less
influenced by patient effort or examiner variability [Wren et al, 2008]. Indeed Arpan et al
demonstrated that boys with DMD treated with corticosteroids demonstrated a slower 

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 38 of 89
CONFIDENTIAL
rate of fat accumulation in the soleus and vastus lateralis muscles compared to 
corticosteroid-naive boys as measured by MRI/magnetic resonance spectroscopy (MRS) 
[Arpan et al, 2014].  
There is increasing recognition of the effect of cardiomyopathy on morbidity and 
mortality in DMD, and improved strategies are needed to change the natural history of 
declining left ventricular systolic function and to attenuate its sequelae. There is also a 
need to slow down the loss of respiratory function in patients with this disease. Therefore 
Cohort 3 will also examine whether the potentially observed utrophin modulation 
improves MRI cardiac parameters (such as extracellular volume fraction (ECV), left 
ventricular strain, left ventricular ejection fraction, end-diastolic and end-systolic 
volumes (EDV), and late gadolinium enhancement of left ventricular mass) and 
respiratory function parameters (such as forced expiratory volume in 1 second (FEV1), 
forced vital capacity (FVC) maximum inspiratory pressure (MIP), maximum expiratory 
pressure (MEP) and peak expiratory flow (PEF)). Results from this cohort will also 
facilitate the design of a pivotal study.
To date, there are several ongoing large natural history studies in the DMD population. 
Summit will endeavour to access these data in order to compare age and genotype 
matched controls with functional status with boys in Cohort 3 of this open-label study.
1.3. 
Potential Risks and Benefits to Human Subjects 

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 39 of 89
CONFIDENTIAL
1.3.2.
Healthy Volunteer Safety Summary
Thirty-seven healthy subjects in study SMT C11001 were exposed to SMT C1100 (F2). 

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 40 of 89
CONFIDENTIAL
SMT C1100 was well tolerated, with the majority of reported AEs being mild in severity
and resolving without treatment. No severe AEs or SAEs have been reported. The only
drug-related AEs were pale and/or discoloured stools, reported, predominantly, at the
higher dose levels of 0.4 g/kg (single dose) and 0.2 g/kg (bid). These AEs were not
associated with any other gastrointestinal-related AEs and are probably a consequence of 
a greater proportion of unabsorbed study drug passing through the gastrointestinal tract at
the higher dose levels. No apparent treatment- or dose-related trends in the 12-lead ECG
parameters were noted. In particular, there was no evidence of prolongation of QTc
interval at each dose level of SMT C1100. No individual subjects had a QT interval, heart
rate corrected using Fridericia’s formula (QTcF) >480 ms following dosing of SMT 
C1100. In addition no subjects had an increase from baseline in QTcF >60 ms; three
subjects had a maximal QTcF change in baseline of >30 ms.  
Sixteen healthy male subjects enrolled in Part A of the SMT C11004 study. Eight 
subjects received SMT C1100 oral nanosuspension (F5) at doses of up to 6 g bid, and 
eight subjects received SMT C1100 powder for oral suspension (F6) at doses of up to 4 g 
bid. One subject who received F6 4 g bid (fed) discontinued after 4 days of dosing due to 
a TEAE of abdominal discomfort considered possibly related to study drug. All 16 
subjects reported TEAEs, the majority of which were mild. ‘Discoloured faeces’ was the 
most frequently-reported TEAE. Headache and Nausea were related AEs reported with 
the nanosuspension and Change of Bowel Habit, Abdominal Discomfort, Faeces Pale, 
Abdominal Pain, Diarrhoea, Dyspepsia and Nausea were related AEs reported for the 
powder for oral suspension formulation. Transient increases in liver-related laboratory 
tests were observed during the dosing period, though no subject satisfied any of Hy’s 
criteria and values returned to baseline after dosing had stopped. As a precaution, and 
because these elevations may be masked in the DMD population, who already have 
abnormal liver function tests (LFTs), glutamate dehydrogenase (GLDH) was also 
monitored in Part B together with amylase and lipase to assess pancreatic function.
1.3.3.
Duchenne Muscular Dystrophy Patients Safety Summary
Thirty-two boys with DMD have taken part in three studies with SMT C1100. However 
as several of the boys have taken part in more than one study, 22 individual boys with 
DMD have been exposed to SMT C1100 in total. 
In Study SMT C11002 (F2) involving 12 paediatric patients with DMD, SMT C1100 was 
well tolerated, with the majority of reported AEs being mild in severity. No severe AEs or 
SAEs were reported. The most frequently related drug-related AEs were pale stools, 
which were predominantly reported at the higher dose intervals of 0.1 g/kg bid and 0.1 
g/kg tid. In study SMT C11002 at doses of up to 0.1 g/kg bid there were no significant
QTc changes in ECGs. Only one patient had an increase from baseline  ms in the 
QTcF although all his QTcF values were <400 ms.

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 41 of 89
CONFIDENTIAL
In Study SMT C11003 (F3) all 12 patients experienced at least one TEAE while receiving
each of the three treatments, including placebo. It is important to note that placebo included 
excipients to mimic pale stool colour in order to maintain the blind. There were no severe or 
serious AEs, and no patient discontinued due to an AE. All AEs were considered mild or 
moderate by the investigator. The most common TEAE in the study, was pale stools, 
reported by all twelve patients (100%) receiving SMT C1100 and 9 patients (75%) 
receiving placebo.
ECG data for study SMT C11003 showed that in neither the placebo nor active groups did 
any patient display a maximum increase in QTcF of  ms. Nine (75%) patients in the 
placebo group had a maximum increase in QTcF of between 30–59 ms, compared to four 
(33%) patients in the 1.25 g bid group and three (25%) patients in the 2.5 g bid group. 
The maximum QTcF (average of replicates) recorded was 453 ms seen at the 2.5 g bid 
level. Mean increases from baseline were less than 10 ms for all groups, except the 
placebo group, across all time points. No significant difference was seen between the 
active and placebo groups for median changes in heart rate.  
Overall, SMT C1100 was considered safe and well tolerated in study SMT C11003 in
paediatric patients with DMD.
As described above and in the Investigator’s Brochure, data from hERG studies with SMT 
C1100 and its major metabolites (DHD I and DHD III) indicated low risk of hERG
channel blockade effects, given the actual plasma levels of  DHD I and DHD III seen after
dosing with SMT C1100. In study SMT C11003, DHD III levels in the patients with
DMD exceeded the maximum level seen in the female rat. However, no significant
changes in QTcF were seen in patients with DMD dosed with 2.5 g bid for 14 days.
Specifically the patient with DMD with the highest SMT C1100 exposure also had the 
highest level of DHD III following the 1.25 g bid dose but did not have the longest QTcF.
The maximum mean QTcF of 453 ms was seen in another patient at the 2.5 g bid dose 
level.
In study SMT C11004 examining the F6 formulation, seven of the eight patients 
experienced at least one TEAE, with all but one event being considered mild or moderate 
by the Investigator. The one severe event was also the one SAE (raised LFTs). Three 
patients were withdrawn from the study, two of which discontinued due to TEAEs (raised 
LFTS (0.25 g bid dose) and abdominal pain (1 g bid dose)). The most frequently reported 
TEAEs were diarrhoea (three patients), abdominal pain (two patients), abdominal pain 
upper (two patients) and pale faeces (two patients). All were considered at least possibly 
related to treatment, except one patient's diarrhoea and one patient's abdominal pain 
upper. 
Patients with DMD have elevated AST and ALT (of muscle origin) as part of their 
disease pathology. In non-DMD patients the potential for severe hepatotoxicity may be 

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 42 of 89
CONFIDENTIAL
signalled by a set of findings sometimes called Hy’s Law that includes an increase in 
leakage enzymes such as ALT and AST that may signal hepatocyte necrosis along with 
an increase in bilirubin suggesting a functional deficit. However, in DMD patients this 
rule is difficult to implement given that patient’s AST and ALT are already elevated as 
part of their disease. Total bilirubin was raised (>ULN) in three of the eight patients 
during the dosing periods in SMT C11004. GLDH, another leakage enzyme, is thought to 
be a more reliable indicator of liver cell necrosis particularly in DMD patients and was 
raised (>ULN) in five of eight patients during the dosing periods. However, the increased 
GLDH was not dose dependent and the elevation was minimal with only one patient 
having a value >2x ULN.  
In Study SMT C11004, there were no clinically significant increases in QTcF. No patient 
had a QTcF of >450 ms and no patient had a QTcF value increase by more than 60 ms.
Overall, SMT C1100 was considered safe and well tolerated in study SMT C11004 in
paediatric patients with DMD although based on the liver function findings additional 
monitoring of these parameters and coagulations function (changes in which can also 
indicate liver damage) will be undertaken in Cohorts 2 and 3. 
1.3.4.
Risk Mitigation in Study SMT C11005
Three potential drug-related risks have been identified. One related to inhibition of the 
hERG channel by DHD I and DHD III, one related to potential interactions with 
concomitant medications, and one related to liver function test changes seen with F6. 
The major metabolites of SMT C1100, DHD I and DHD III, caused between 25–45% 
inhibition of the hERG and human voltage-dependent calcium channel hCav1.2 at 30 μM. 
The highest individual plasma concentrations seen in patients dosed with F3 or F6 was at 
least 54-fold or 22-fold, respectively, below 30 μm for free DHD I and DHD III, and thus 
unlikely to cause QTc prolongation. However as a precaution and as this patient 
population is known to have significant ECG abnormalities and conduction defects, in this 
current and in previous clinical studies with patients with DMD, ECGs are being assessed
frequently. 
The preclinical pharmacokinetic studies indicated that SMT C1100 was primarily 
metabolized by CYP1A1 and CYP1A2. It was also shown that SMT C1100 could inhibit 
CYP1A1 and CYP1A2 in vitro; however, this inhibition was determined not to be 
clinically significant based on PBPK/Simcyp modelling (Study No. N-135). The 
metabolites of SMT C1100, DHD I and DHD III, were shown to induce CYP2B6.  Based 
on the above, medication that induce CYP1A1 and/or CYP1A2 are restricted as are 
substrates of CYP2B6.  

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 43 of 89
CONFIDENTIAL
SMT C1100, DHD I, and DHD III inhibited BCRP in vitro so given the role of this 
transporter in drug disposition and distribution, BCRP substrates are being excluded. 
DHD I and DHD III also inhibited OATP1B1 and OATP1B3 hepatic uptake transporters 
which could alter efficacy and increase the risk of exposure-dependent side effects of 
OATP1B1 and OATP1B3 substrates. Therefore, patients taking medications that are 
OATP1B1/1B3 substrates should be monitored for exaggerated pharmacological effects 
and exposure-dependent side effects as dose reduction may be needed. OATP1B1/1B3 
substrates fluvastatin and rosuvastatin are also BCRP substrates and therefore excluded. 
Further details are provided in Section 9.2. 
Abnormal liver function tests were seen in patients with DMD dosed with the F6 
formulation in the SMT C11004 study. AST and ALT are enzymes already raised in 
patients with DMD (although the likely source is muscle) and, as such, further elevations 
in these enzymes due to liver toxicity may be difficult to see. GLDH is being evaluated 
and is considered a more specific liver enzyme marker [Schomaker et al, 2013]. In 
addition, liver disease is characterised by reduced synthesis of the procoagulant proteins 
II, VII, IX, X, as well as factor V and factor XI. These factor deficiencies directly affect 
the standard coagulation measures available in clinical laboratories, mainly the 
prothrombin time (PT) and its standardisation, the international normalised ratio (INR), 
and to a lesser extent, the activated partial thromboplastin time (aPTT) [Northup and 
Caldwell, 2013]. Therefore, as a precaution and as a means to monitor liver dysfunction 
both GLDH and coagulation times will be measured. 
Finally, during the SMT C11004 study stopping criteria based on liver function were 
developed. These are outlined below and will be followed during this study, as 
applicable.
If a patient’s results meet either of the criteria below, dosing should be stopped and the 
tests should be repeated as soon as possible. If the repeated results still meet this 
criterion, the study drug will be permanently stopped and may not be restarted although 
the patient will continue to be followed for functional and MRI assessments for the 
duration of the study. If the patient is withdrawn from the study, a follow up visit should 
be arranged: 
*/'+[XSSHUOLPLWRIQRUPal (ULN) 
OR
%LOLUXELQ[8/1WRJHWKHUZLWKDQ,15[8/1&RKRUWDQGRQO\
Patients in this study will receive either SMT C1100 2.5 g bid F3 formulation (Cohort 1 
and Cohort 3) or SMT C1100 1 g bid F6 formulation (Cohort 2) for 48 weeks. Previous 
exposure at the F3 formulation 2.5 g bid dose level in the paediatric DMD population has 

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 44 of 89
CONFIDENTIAL
been limited to 14 days whilst that for F6 formulation 1 g bid dose level has been limited 
to 7 days. Neither has been associated with any safety signals except the observation of 
pale stools with both formulations and transient elevations in LFTs for the F6 
formulation. The pharmacokinetics of SMT C1100 parent and metabolites, and the safety 
data, will be reviewed on an ongoing basis by the Sponsor and the data monitoring 
committee (DMC). As this is an open-label study, the Investigator should determine if an 
SAE is related to IMP and consider modifying the dose given. Serious AEs considered at 
least possibly related to IMP may require a dose reduction, a temporary hold or 
permanent discontinuation, with prior consultation and agreement with the Sponsor. 
A risk relating to the study design is the requirement for the paediatric patients enrolled in
this study to undergo up to two muscle biopsies, which will include the use of 
anaesthesia. This procedure may cause some discomfort but will be done with the assent
of the patient, consent of their parents (or other adult legally responsible for them) and ina 
sensitive way that takes into account their age. The procedure will be explained to the 
patients in advance in an age appropriate manner and they and their parents will be given
an opportunity to ask any questions they have relating to the procedure. Appropriate pain-
relief will be made available following each biopsy. 
1.3.5.
Risk Benefit Statement
Currently there is no cure for DMD although two treatments (one in the USA and one in 
the EU) for a subset of boys with specific dystrophin gene mutations are available. The 
average life-span of patients with DMD is 25–30 years [Merlini et al, 2015].  
This is the first Phase 2 study being performed with this compound and so is the first
study to examine activity of SMT C1100 in patients with DMD. As such, it is not possible 
to say whether there will be any benefit to those taking part in the study. It is thought that
exposure over this length of time will maintain the expression of utrophin in muscle, and 
potentially this will be beneficial. Investigations and assessments will be undertaken to see 
if these changes have a positive effect on MRI and for monitoring disease progression by 
evaluating muscle fat infiltration and inflammation - both considered markers of disease 
progression in patients with DMD.  
The aim of SMT C1100 is to modulate the levels of utrophin in muscle fibres in order to 
reduce continued muscle deterioration in boys with DMD and it is theoretically likely to
benefit those boys with adequate muscle mass and who are ambulatory. It is appropriate 
therefore in this situation to enrol a younger (WRyears) population as patients with
DMD usually become wheelchair bound between the ages of 8–12 [Uzark et al, 2012]).
However, data also show that cardiac contractile dysfunction of mdx mice is generally 
worsened in mice also lacking utrophin [Janssen et al, 2005] Indeed one of the leading 
causes of death in patients with DMD is cardiomyopathy. It is therefore appropriate to 

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 45 of 89
CONFIDENTIAL
investigate a utrophin modulator in patients with DMD who may be older or have a 
reduced functional and cardiac status such as those expected to be enrolled in Cohort 3. 
To date, no major safety signal has been observed in either the animal toxicology studies 
or in the human clinical studies. Preclinical data suggests an interaction with the hERG 
channel, interactions with substrates of CYP2B6 and BCRP, and inhibition of the MAO-
B enzyme. These risks are mitigated by the assessment of multiple ECGs taken at 
frequent time points throughout the study, the exclusion of substrates of CYP2B6 and 
BCRP and the exclusion of drugs that have serotonergic, norepinephrinergic or 
dopaminergic activity. One SAE was reported following dosing with the F6 formulation 
in Study SMT C11004 but no SAES reported in the ongoing PhaseOut DMD study (SMT 
C11005) with the majority of AEs reported being mild (data up to 07 Feb 2017). 
Although abnormal LFTs have previously been seen in patients with DMD treated with 
the F6 formulation, these abnormal values quickly returned to baseline levels after dosing 
with the IMP was stopped. Additional safety tests including GLDH and measurement of 
coagulation parameters have been added to the protocol and robust stopping criteria 
defined. Subjects in the SMT C11005 study may continue to receive SMT C1100 
following their Week 48 visit, and will provide long term safety data, useful long term 
efficacy data, and also provide an opportunity to compare any beneficial effects to natural 
history data.  
The Sponsor therefore believes the current risk benefit ratio for the SMT C11005 study is 
favourable.  
However, the Sponsor will immediately notify the Principal Investigators and Regulatory 
Agencies if any additional safety or toxicology information becomes available during the 
study. In addition, an independent DMC will, on a regular basis, review all pertinent 
pharmacokinetic and safety data and make recommendations on dosage adjustments, if 
needed during the main part of the study. 
2. 
OBJECTIVES 
All objectives apply to all cohorts unless otherwise specified. 
2.1.
Primary Objectives
x
To investigate changes in leg MRI in paediatric patients with DMD, 
following treatment with SMT C1100 (Cohorts 1 and 2) 
x
To investigate the relationships between changes in leg MRI with plasma 
concentrations of SMT C1100 and its metabolites in paediatric patients with 
DMD, following treatment with SMT C1100 (Cohorts 1 and 2) 

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 46 of 89
CONFIDENTIAL
x
To assess the safety and tolerability of SMT C1100 and its metabolites in 
paediatric patients with DMD
2.2.
Secondary Objectives
x
To investigate changes in utrophin expression and muscle fibre regeneration in 
muscle, in paediatric patients with DMD, following treatment with SMT 
C1100 (Cohorts 1 and 2) 
x
To investigate the relationships between changes in utrophin expression and fibre 
regeneration in muscle and safety parameters with plasma concentrations of SMT 
C1100 and its metabolites in paediatric patients with DMD, following treatment 
with SMT C1100 (Cohorts 1 and 2) 
x
To investigate changes in pulmonary function tests in paediatric subjects with 
DMD, following treatment with SMT C1100 
x
To investigate the relationships between changes in pulmonary function tests with 
plasma concentrations of SMT C1100 and its metabolites in paediatric subjects 
with DMD, following treatment with SMT C1100 
2.3. 
Exploratory Objectives 
x
To investigate changes in functional measures, in paediatric patients with DMD, 
following treatment with SMT C1100, including the relationship between functional 
measures and exposure 
x
To investigate changes in paediatric outcomes data collection instrument (PODCI) 
scores in paediatric patients with DMD, following treatment with SMT C1100, 
including the relationship between PODCI scores and exposure  
x
To investigate changes in blood biomarkers in paediatric patients with DMD, 
following treatment with SMT C1100, including the relationship between blood 
biomarkers and exposure 
x
To investigate changes in cardiac MRI tests in paediatric subjects with DMD, 
following treatment with SMT C1100 (Cohort 3) 
x
To investigate the relationships between changes in cardiac MRI with plasma 
concentrations of SMT C1100 and its metabolites in paediatric subjects with DMD, 
following treatment with SMT C1100 (Cohort 3) 
3.
ENDPOINTS
All endpoints apply to all cohorts unless otherwise specified. 

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 47 of 89
CONFIDENTIAL
3.1.
Primary Endpoints
x
Change from baseline to Weeks 12, 24, 36 and 48 in MRI leg muscle parameters 
(Cohorts 1 and 2)  
x
SMT C1100 and metabolite plasma concentrations at Weeks 1 (Days 1 and 7, as 
applicable (Cohorts 2 and 3 only)), 4, 8 (Cohorts 1 and 2 only), 12, 24, 36 and 48  
x
Safety data including:
x
Treatment emergent AEs
3.2. 
Secondary Endpoints 
x
Change from baseline to Week 24 or 48 in utrophin expression via muscle biopsy 
analysis (Cohorts 1 and 2) 
x
Change from baseline to Week 24 or 48 in muscle regeneration biomarkers via 
muscle biopsy analysis (Cohorts 1 and 2) 
x
Change from baseline to Weeks 12, 24, 36 and 48 (Cohorts 1 and 2) and from 
baseline to Weeks 1, 24 and 48 (Cohort 3) in pulmonary function tests  
x
Safety data including:
x
Vital signs (systolic and diastolic blood pressure and heart rate)
x
Physical examination
x
Twelve-lead electrocardiogram (ECG)
x
Echocardiogram (ECHO) 
x
Pulmonary function tests: 
x
Forced expiratory volume in 1 second (FEV1) 
x
Forced vital capacity (FVC) 
x
Maximum inspiratory pressure (MIP)  
x
Maximum expiratory pressure (MEP)
x
Peak expiratory flow (PEF)
x
Peak cough flow (PCF) (Cohort 3) 
x
Sniff nasal inspiratory pressure (SNIP) (Cohort 3) 
x
Safety laboratory evaluations (clinical chemistry, haematology, (all 3 Cohorts) 
coagulation (Cohort 2 and Cohort 3) parameters and urinalysis (all 3 Cohorts)) 

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 48 of 89
CONFIDENTIAL
3.3. 
Exploratory Endpoints 
x
Change from baseline to Week 12, 24, 36 and 48 (in the main phase of the study) 
measured at 6-monthly intervals for the duration of the Extension Phase in 6MWD 
x
Change from baseline to Week 12, 24, 36 and 48 (in the main phase of the study) 
measured at 6-monthly intervals for the duration of the Extension Phase in North 
Star Ambulatory Assessment (NSAA) global score
x
Change from baseline to Week 12, 24, 36 and 48 (in the main phase of the study) 
measured at 6-monthly intervals for the duration of the Extension Phase in timed 
function tests (10 meter run/walk, time to stand) 
x
Change from baseline to Week 12, 24, 36 and 48 (in the main phase of the study) 
measured at 6-monthly intervals for the duration of the Extension Phase in paediatric 
outcomes data collection instrument (PODCI) scores 
x
Change from baseline to Week 12, 24, 36 and 48 (in the main phase of the study) 
measured at 6-monthly intervals for the duration of the Extension Phase in 
Performance of Upper Limbs (PUL)
x
Change from baseline to Week 12, 24, 36 and 48 (in the main phase of the study) and 
measured at 6-monthly intervals for the duration of the Extension Phase of blood 
biomarkers, e.g., creatine kinase, matrix metallopeptidase 9 and other biomarkers 
x
Change from baseline to Week 48 (in the main phase of the study) and measured at 
12-monthly intervals for the duration of the Extension Phase in cardiac MRI 
parameters (Cohort 3) 
x
Change from baseline in MRI leg muscle parameters measured at 6-monthly 
intervals for the duration of the Extension Phase (Cohorts 1 and 2)  
x
SMT C1100 and metabolite plasma concentrations measured at 6-monthly intervals 
for the duration of the Extension Phase 
x
Change from baseline in pulmonary function tests measured at 6-monthly intervals 
for the duration of the Extension Phase 
It should be noted that patients in Cohort 3 may not be able to perform all of the 
functional tests at baseline. Therefore the patients included in the analyses for these tests 
will be test specific and based upon their baseline ability to perform the test.

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 49 of 89
CONFIDENTIAL
4.
STUDY DESIGN
4.1.
Summary of Study Design
4.1.1.
Study Design
This is a Phase 2, open-label, study to assess the activity and safety of utrophin 
modulation with SMT C1100 administered bid to ambulatory paediatric male patients 
with DMD. In Cohort 1, approximately 30 patients with DMD will receive SMT C1100 
2.5 g bid as the F3 formulation. In Cohort 2, approximately 10 patients with DMD will 
receive SMT C1100 1 g bid as the F6 formulation. In Cohort 3, approximately 
15 patients, who have previously received SMT C1100, but who are not eligible for 
Cohorts 1 or 2, will be administered 2.5 g bid of F3. Cohort 1 will be conducted in the 
UK and USA. Cohort 2 will only be conducted at specific centres in the USA. Cohort 3, 
will only be conducted in the UK.  
This study will be conducted in a multi-centre setting and comprises of a Screening and 
Baseline period of up to 28 days and initially a 48-week open label Treatment Phase. 
Following completion of the 48-week open label Treatment Phase, patients will be 
eligible for rolling on to an Extension Phase which will continue until SMT C1100 is 
approved or discontinued. All patients will receive the same formulation as they had 
previously been receiving, twice-daily, in the Extension Phase. 
Study patients not rolling on to the Extension Phase will complete a 30-day Safety 
Follow up following completion of the initial Treatment Phase. Similarly, when the study 
finishes, all patients still ongoing treatment in the study will cease their study medication 
and complete a 30-day Safety Follow up.  
During the Treatment Phase patients will be dosed at home by their parents/responsible-
adult twice-daily with approximately 8–12 hours between the breakfast dose and evening
meal dose. 
For boys in Cohorts 1 and 3, SMT C1100 will be administered, in the fed state, as the F3 
formulation and with a glass of whole/full-fat milk. A suitable number of syringes will be 
provided with the IMP and the volume prescribed will relate to the gradations on the 
measuring device. 
For boys in Cohort 2, SMT C1100 will be administered in a fed state with the F6 
formulation constituted in milk prior to immediate administration. A suitable number of 
graduated dosing cups will be provided with the IMP. Patients in Cohort 2 will be 
required to attend an additional visit for blood sampling on Day 7. 

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 50 of 89
CONFIDENTIAL
A maximum of two muscle biopsies (Cohorts 1 and 2 only) will be taken one of which 
will be at baseline. Where the procedure is performed at screening this will be after the 
patient has been confirmed eligible for the study.  
The patients in Cohorts 1 and 2 will be assigned as to when they will receive the second 
muscle biopsy procedure. The first eight patients enrolled in Cohort 1 will have a biopsy 
at 24 weeks and the remaining 22 patients will be assigned alternately between the 24-
week and the 48-week time point. The first 6 patients enrolled in Cohort 2 will have the 
biopsy at the 24-week time point and the remaining 4 patients will have theirs at the 48 
week time point.
If preferred by the site and patient’s family then the visits at Day 7 (Cohort 2 and 3 only) 
and Weeks 4 (all Cohorts) and 8 (Cohorts 1 and 2 only) may be performed at the patient’s 
house by a sponsor-provided home-nursing team.  
Patients who withdraw early from the study will be asked to return for an Early 
Termination Visit at which, if the patient agrees, the second biopsy will be performed (if 
it has not already been completed) as well as other safety and functional assessments. If 
patients are not willing to return then this will be documented in the source documents 
and case report form (CRF) and will not be classed as a protocol deviation. 
Details on the timing of treatment and assessments are given in the Time and Events 
Table.  
4.1.2.
Duration of Patient Participation
Patients will initially be involved (from screening to follow-up) in the study for 
approximately 52–56 weeks. This period includes a screening and baseline period that 
will last up to 28 days, a 48-week Treatment Phase and a potentially a 30-day safety 
follow up. 
Patients who complete the 48-week open label Treatment Phase may choose to consent to 
roll into an Extension Phase which will last until either SMT C1100 is approved in the 
relevant countries or development of SMT C1100 is discontinued. Patients who are 
enrolled in the Extension Phase may have home visits if only vital signs and blood 
samples are being collected at a scheduled visit (Weeks 12 and 36 of each year of the 
Extension Phase); if this occurs then AE and concomitant medication checks will be 
performed in a documented telephone call. The patient’s IMP supply should be 
considered when determining whether a home and telephone visit are appropriate. 
Patients in the Extension Phase will have a 30-day safety follow up if/when the study is 
stopped. 

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 51 of 89
CONFIDENTIAL
Additionally, the DMC and/or the Sponsor may recommend amending the duration of the 
study based on safety or efficacy findings.  
4.2.
Stopping Rules
4.2.1.
Study Stopping Rules
Routine independent DMC meetings will be held during the course of the study in 
accordance with ICH-GCP and the DMC charter. Additional meetings can be requested 
at the DMC’s discretion at any point in the study.
The responsibilities of the DMC include: (1) ongoing assessment of safety data during 
the trial for the purposes of safeguarding the interests of trial participants, (2) assessment 
of pharmacokinetic data and its relationship to the AE profile, (3) oversight of clinical 
trial conduct including general safety and International Council on Harmonization (ICH) 
GCP procedures. To enhance the integrity of the trial, the DMC may formulate 
recommendations relating to the selection/recruitment/retention of patients, improving 
adherence to protocol-specified treatment and retention of patients and procedures for 
data management and quality control. Based on its review of the data during periodic 
meetings, the DMC may provide recommendations about stopping, modifying, or 
continuing the trial. Summit will retain ultimate responsibility on decision making.
Summit reserves the right, at any time, to prematurely terminate the trial or trial sites. 
Premature termination of the trial could be for scientific or administrative reasons or for 
any other valid and/or ethical reason or if any safety issues arises and the overall 
risk/benefit evaluation changes and is no longer in favour of continuation. 
4.2.2.
Individual Stopping Rules
The pharmacokinetics of SMT C1100 parent and metabolites, and their relationship with 
all safety parameters, will be reviewed on an ongoing basis by the Sponsor and the DMC. 
As this is an open-label study, the decision to stop individual patients may be made on a 
case-by-case basis. The DMC can also recommend, in individual patients, a lowering of 
the SMT C1100 dose. 
If a patient’s results meet either of the criteria below, dosing should be stopped and the 
tests should be repeated as soon as possible. If the repeated results still meet this 
criterion, the study drug will be permanently stopped and may not be restarted although 
the patient will continue to be followed for functional and MRI assessments for the 
duration of the study. If the patient is withdrawn from the study, a follow up visit should 
be arranged:  
•
*/'+[8/1

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 52 of 89
CONFIDENTIAL
OR
•
%LOLUXELQ[8/1WRJHWKHUZLWKDQ,15[8/1&RKRUWDQGRQO\
Any intolerable AE or SAE that is at least possibly related to study drug should lead to a 
temporary discontinuation of the patient’s study treatment. After resolution of the 
intolerable AE or SAE, the Investigator, in discussion with the Sponsor, may decide to 
either permanently discontinue the patient’s study treatment, or, if recommended by the 
DMC and Sponsor reinstate treatment but reduce their bid dose to 1.25 g for Cohort 1 and 
3 or reduce the frequency to once-daily dosing (2.5 g or 1.25 g for Cohorts 1 and 3; 1 g 
for Cohort 2; see Section 8.1.1). If a lowered dose is tolerated for at least 2 weeks the 
Investigator can, based on the recommendation of the DMC and Sponsor escalate the 
dose up to the original strength. Once-daily dosing should occur in the morning. 
5.
STUDY POPULATION
5.1. 
Number of Patients 
A suitable number of potential patients will be screened in order that approximately 
55 patients successfully meet the inclusion and exclusion criteria and continue into the 
Treatment Phase. Approximately thirty patients are expected to be enrolled in Cohort 1, 
approximately 10 in Cohort 2 and approximately 15 in Cohort 3. The sample size is not 
based upon statistical powering, but the number is considered as sufficient to initially 
explore the endpoints and their relationship with SMT C1100 plasma exposure. 
Patients who withdraw or who are withdrawn during the Treatment Phase may be 
replaced if the study has not yet reached full enrolment at the time of withdrawal. Patients 
who withdraw or who are withdrawn for an AE considered related to SMT C1100 will 
not be replaced.
Efforts will be made, in Cohorts 1 and 2, to balance the study populations and attempt to 
have at least 50% of the boys with a fat:water fraction greater than or equal to 0.15. 
Efforts will also be made such that half of the boys are greater than or equal to 8 years of 
age at screening. Such attempts will be made manually rather than via an automatic 
system; achieving these recruitment goals will be attempted but complete balance will not 
be enforced.
All patients in Cohorts 1–3, will be eligible to be rolled into the Extension Phase.

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 53 of 89
CONFIDENTIAL
5.2.
Eligibility Criteria
5.2.1.
Main Study
5.2.1.1.
Inclusion Criteria
To be enrolled patients must meet all selected criteria for their cohort:
Criterion 
Number
Criterion
Cohort 
1
Cohort 
2
Cohort 
3
1
Be able to provide written informed consent/assent as per local requirements.
9
9
9
2
Be male
9
9
9
3
%HDJHG\HDUVWR\HDUVRIDJHIURPth birthday to 10th birthday)
9
9
NA
4 
Have phenotypic evidence of dystrophinopathy based on the onset of characteristic clinical symptoms or signs (e.g., proximal muscle 
weakness, waddling gait, and Gowers' manoeuvre), an elevated serum creatinine kinase level, and ongoing difficulty with walking
9
9
9
5 
Have prior confirmation of the DMD diagnosis through:
Documentation of the presence of a mutation in the dystrophin gene as determined by gene sequencing from a laboratory certified
by the College of American Pathologists, the Clinical Laboratory Improvement Act/Amendment or an equivalent organisation. 
Or  
Documentation of the absence of dystrophin in the muscle (via biopsy)
9
9
9
6
Be willing and able to comply with two muscle biopsy procedures
9
9
NA
7
Be able to undergo MRI examination
9
9
9
8 
Patients must have used stable systemic corticosteroids (prednisone, prednisolone or deflazacort) for a minimum of 6 months 
immediately prior to the start of the Treatment Phase, with no significant change in dosage or dosing regimen (not related to body weight 
change) and a reasonable expectation that dosage and dosing regimen will not change significantly for the duration of the study
9
9
9
9 
Have the ability to walk at least 300 meters unassisted during the screening 6MWD and be below the protocol-specified threshold for 
80%-predicted 6MWD
9
9
NA
10
Have results of two 6MWD by Baseline determined as valid. The results of the second 6MWD (baseline) must be within 20% of the first 
6MWD (screening)
9
9
NA
11
Have cardiac ECHO measurements showing an ejection fraction of 55% and fractional shortening of 28%
9
9
NA
12
Confirmed screening laboratory values within the central laboratory ranges (haematology, renal and serum electrolyte parameters and 
9
9
9

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 54 of 89
CONFIDENTIAL
Criterion 
Number
Criterion
Cohort 
1
Cohort 
2
Cohort 
3
serum chemistry parameters) or considered not clinically significant in the opinion of the Investigator. Variations in specific parameters 
expected in a DMD population (e.g., AST, ALT, alkaline phosphatase, lactate dehydrogenase and CPK) classed by the Investigator as not 
clinically significant will not exclude the patient
13
Be willing and able to comply with scheduled visits, drug administration plan, study procedures, laboratory tests and study restrictions
9
9
9
14
Have taken part in a prior SMT C1100 study
NA
NA
9
5.2.1.2.
Exclusion Criteria
To be enrolled patients must not meet any of the selected criteria for their cohort:
Criterion 
Number
Criterion
Cohort 
1
Cohort 
2
Cohort 
3
1 
Have physical exam findings that in the investigator’s opinion should be exclusionary e.g., lower limb injury that may affect 6MWD 
performance
9
9
9
2 
Have any change (initiation, change in type of drug, dose modification, schedule modification, interruption, discontinuation or reinitiation) 
in prophylaxis/treatment for congestive heart failure (CHF) within 3 months prior to the start of study treatment
9
9
9
3
Have uncontrolled clinical symptoms and signs of CHF (American College of Cardiology/American Heart Association Stage C or Stage D)
9
9
9
4
Have abnormal GLDH at baseline (>1.5 x ULN)
9
9
9
5
Have abnormal coagulation times at baseline (>1.5 x ULN)
9
9
6
Have an abnormal ECG e.g., a QTcF >500 ms, left bundle-branch block or any other major conduction defect
9
9
9
7
Use beta blockers (however, if during the course of the study they are clinically indicated they can be initiated)
9
9
NA
8
Use herbal supplements and be unwilling to stop these for the duration of the study
9
9
9
8 
Have a known hypersensitivity to any of the ingredients or excipients of the IMP. microfluidised oral suspension (F3): Poloxamer 188, 
Methylparaben, Propylparaben, Hydroxypropylmethyl cellulose, Glycerol, Non crystallising sorbitol [70%], Xanthan gum, Strawberry 
cream flavour [PHS-132963]
9
NA
9
10
Have a known hypersensitivity to any of the ingredients or excipients of the IMP. Powder for oral suspension (F6): hypromellose acetate 
succinate
NA
9
NA
11
Have been exposed to another investigational drug or DMD interventional agent within 3 months prior to start of the Treatment Phase. 
Prior exposure to SMT C1100 or participation in an approved deflazacort access program (e.g., FOR-DMD or ACCESS DMD clinical 
trials) within this period would not exclude the patient (provided they have been on stable treatment for 6 months)
9
9
9

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 55 of 89
CONFIDENTIAL
Criterion 
Number
Criterion
Cohort 
1
Cohort 
2
Cohort 
3
12
Have a history of major surgical procedure within 12 weeks prior to the start of the Treatment Phase (Week 1)
9
9
9
13
Be undertaking ongoing immunosuppressive therapy (other than corticosteroids)
9
9
9
14
Have an expectation of a major surgical procedure (e.g., scoliosis surgery) during the 12-month Treatment Phase of the study
9
9
9
15
Require daytime ventilator assistance
9
9
9
16
Have a prior or ongoing medical condition (e.g., concomitant illness, psychiatric condition, behavioural disorder, alcoholism, drug abuse), 
medical history, ECG findings, or laboratory abnormality that, in the Investigator's opinion, could adversely affect the safety of the patient, 
makes it unlikely that the course of treatment or follow-up would be completed, or could impair the assessment of study results
9
9
9
17
Be dairy or lactose intolerant or have any other dietary restrictions that might interfere with the conduct of the study
9
9
9
18
Be a smoker, use other tobacco or nicotine products or be exposed to daily passive smoking (including parent/legal guardian, siblings) so 
as to minimise environmental factors causing CYP1A induction
9
9
9
19
Be using an approved DMD medication or anticipates using one during the duration of the study e.g., ataluren, idebenone, drisapersen, 
Exondys51. Patients who are taking part in the FOR-DMD and ACCESS DMD studies will be allowed to take part
9
9
9
20
Be using an inducer of CYP1A1 or CYP1A2
9
9
9
21
Be using a substrate of CYP2B6
9
9
9
22 
All prescription, OTC, and herbal products that are known CYP2B6 sensitive substrates (e.g., buproprion, efavirenz) will be excluded 14 
days prior to study conduct (beginning at screening) through 14 days after study conduct completion. Please note, this is not an
exhaustive list of CYP2B6 substrates and a discussion with the Medical Monitor may be warranted
9
9
9
23 
Be using drugs that have serotonergic, norepinephrinergic or dopaminergic activity (e.g., selective serotonin reuptake inhibitors, serotonin 
norepinephrine reuptake inhibitors, tricyclic antidepressants, tryptophan, dextromethorphan, meperidine, bupropion, nortriptyline, 
desipramine, doxepin, amoxapine, rasagiline, selegiline), or treatments used in attention deficit hyperactivity disorder such
as Methylphenidate, and phenethylamine (PEA)
9
9
9
24 
Use of substrates of BRCP (e.g., omeprazole, rabeprazole, fluvastatin, methotrexate, mitoxantrone, imatinib, irinotecan, lapatinib, 
rosuvastatin, sulfasalazine, topotecan)
9
9
9
.

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 56 of 89
CONFIDENTIAL
6.
STUDY ASSESSMENTS AND PROCEDURES
Each study patient in Cohorts 1 and 2 will require overnight hospitalisation at four time 
points during the study: Baseline, Week 24, Week 48 and End of study (Week 52). The 
purpose of these residential stays is to minimise patient activity immediately prior to 
certain biomarker assessments (i.e., CK) and physiological assessments (i.e., 6MWD, 
NSAA) as well as to facilitate pharmacokinetic sampling when conducted post-PM dose. 
Patients enrolled in Cohort 3 will not be required to attend residential stays. 
Additional overnight hospitalisation may be requested to fit institutional requirements 
regarding biopsy or MRI procedures, however, this is not required. 
6.1. 
Screening Procedures 
6.1.1.
Medical History
The patient’s medical history will be collected by the Investigator, or suitably qualified 
designee. The information will be collected via an interview with the patient’s parents or 
responsible adult and should include all diseases or conditions identified as relevant by 
the Investigator. The patient should be excluded from the trial if any disease or condition 
listed in the exclusion criteria is detected. 
6.1.2.
Demographics
The following demographic information should be recorded: 
x
Date of birth
x
Sex
x
Race 
x
Ethnicity (Hispanic/Latino or non-Hispanic/Latino)
Information that could identify the patient such as name, initials, social security number, 
(national) insurance number, etc. shall not be recorded in the CRF and should not be 
transmitted from the site to the Sponsor. 
6.1.3.
Nutritionist Appointment
The patient and their parents/responsible adult will meet with a nutritionist at the end of 
the screening process to discuss the nutritional requirements of the patient while they are 
enrolled in the study. 

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 57 of 89
CONFIDENTIAL
6.2. 
Pharmacodynamic Procedures
6.2.1.
Muscle Biopsy
Each patient in Cohorts 1 and 2 will undergo two muscle biopsies during the study at the 
times outlined in the Time and Events Table. Cohort 3 will not undergo muscle biopsies. 
The first eight patients in Cohort 1 will have a biopsy at 24 weeks and the remaining 22 
patients will be alternately assigned between the 24 week and the 48 week time points. 
Six patients in Cohort 2 will undergo their second biopsy at 24 weeks and the remaining 
four patients at Week 48. The patient may have to travel and have the biopsy procedure 
undertaken at a different location to the patient’s usual site of care. Ultrasound guidance 
is recommended though not required. 
Patients who do not complete the 48-week dosing period may have their second biopsy at 
or around the Early Termination visit if it has not already been performed and they are 
willing to do so. 
A detailed description of the methods relating to the collection of the biopsy sample and 
the processing of the sample can be found in the reference manuals. In order to detect 
whether daily dosing with SMT C1100 modulates the effect of utrophin with 
corresponding reduction in fibre regeneration within a muscle biopsy, the levels of 
utrophin protein at the myofibre membrane will be calculated for all fibres found in a 
biopsy section. In parallel, the quantity of regenerating fibres will also be calculated 
using markers of regeneration namely myosin protein intensity and myofibre cross 
sectional area.
Biopsy sampling may be performed using local or general anaesthetic according to the 
Investigator’s clinical judgment as to which route is better for the patient. The biopsy 
should be taken from the biceps muscle. 
6.2.2.
Blood Biomarkers
Blood samples for analysis of biomarkers should be collected at the times outlined in the 
Time and Events Table.
Blood samples should be collected and details on collection and processing can be found 
in the laboratory manual. If patients have consented blood samples will be retained for 
future biomarker analysis.  

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 58 of 89
CONFIDENTIAL
6.2.3.
Magnetic Resonance Imaging
6.2.3.1.
Leg Scan
Patients in Cohorts 1 and 2 will undergo MRI/MRS scans of the leg at the times outlined 
in the Time and Events Table. 
The MRI scans will be performed using a 3 Tesla whole body instrument. The same 
machine should be used for all scans for an individual patient.  
Further details on the MRI procedures can be found in the study reference manual. 
Patients should refrain from exercise for 24 h prior to each MRI procedure. Scans may be 
performed at a different location to the patient’s usual site.
6.2.3.2.
Cardiac Scan
Patients in Cohort 3 will undergo cardiac MRI scans at the times outlined in the Time and 
Events Table.
The MRI scans will be performed using a 3 Tesla whole body instrument. The same 
machine should be used for all scans for an individual patient.  
Further details on the MRI procedures can be found in the study reference manual. Scans 
may be performed at a different location to the patient’s usual site.
6.3. 
Pharmacokinetic Procedures 
Blood samples for analysis of SMT C1100 parent and its metabolites (DHD I and DHD 
III) in plasma will be collected at the times outlined in the Time and Events Table. Day 7 
(Cohort 2 only) and Week 4 and 8 assessments may be conducted by the sponsor-
provided home nursing vendor 
Pharmacokinetic samples for SMT C1100 and metabolites will be measured frequently. 
As this will be a sparse sampling pharmacokinetic assessment each patient in Cohort 1 
and 2 will have three samples taken around either the AM dose or around the PM dose 
only. There will be six time points at which samples can be taken; pre-AM dose, 3 hours 
after the AM dose, 6 hours after the AM dose, or pre PM dose, 4 hours after the PM dose 
and 10 hours (+ up to 4 hours but before the next AM dose) after the PM dose. Sampling 
will be done around the AM dose during Day 1, Weeks 8, 12 and 36 (there is the option 
of samples being collected at the patient’s house at the Week 8 time point). Sampling will 
be done around the PM dose during Weeks 4, 24 and 48 (there is the option of samples 
being collected at the patient’s house at the Week 4 time point). Where the patient has 
been reduced to once-daily dosing only AM sampling points will be undertaken. For 

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 59 of 89
CONFIDENTIAL
subjects in Cohort 2 a single additional sample will be taken at 4 h post-AM dose on Day 
7.
In the Extension Phase all subjects, all cohorts will have a 4 h post-AM dose sample 
taken at the times outlined in the Time and Events Table.
For the 0–8 h samples a ±15 minute window will be allowed for each time point. Further 
details on collection, processing and shipping can be found in the laboratory and shipping 
manuals, respectively.
Samples for determination of SMT C1100 and metabolites (DHD I and DHD III and 
overall metabolite profile, as specified in the laboratory manual) concentrations in plasma 
will be analysed using appropriate bioanalytical methods, which will be described in a 
separate bioanalytical report.
6.4.
Safety Procedures
6.4.1.
Twelve-Lead Electrocardiogram 
Twelve-lead ECGs will be performed at the times outlined in the Time and Events Table.
A single ECG (in triplicate) will be performed at Screening, Baseline, Weeks 12 and 36. 
At Weeks 1, 24 and 48 ECGs will be performed pre-AM dose and 0.5, 2, 4 and 6 h post-
AM dose or pre-PM dose and 0.5, 2 and 4 h post-PM dose. 
Triplicate ECGs separated by approximately 2 to 5 minutes should be collected at each 
time point. The ECGs will be transmitted on an ongoing basis to a centrally based 
cardiologist who will independently examine the ECGs. Further details on performing 
and transmitting ECGs can be found in the Study Reference Manual. 
Measurements will be made using an ECG machine that automatically calculates the 
heart rate and measures PR, RR, QRS, and QT.  
All ECG traces will be reviewed and signed by the PI or a Study Physician and any 
abnormalities will be marked as clinically significant or not clinically significant. If the 
DYHUDJH47F)LV ms then an additional ECG should be repeated after at least a 
5-minute interval. 
6.4.2.
Echocardiogram
Echocardiograms will be performed at the times outlined in the Time and Events Table. 
Patients should rest in a supine position for 10 minutes before the ECHO is performed. 
Further details can be found in the Study Reference Manual.

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 60 of 89
CONFIDENTIAL
6.4.3.
Vital Signs
Vital signs (pulse, respiratory rate, oral temperature and systolic and diastolic blood 
pressure) will be assessed at the times outlined in the Time and Events Table. Patients 
should rest in a supine position for 10 minutes before the vital signs are assessed. 
Patients who are enrolled in the Extension Phase may have home visits if only vital signs 
and blood samples are being collected at a scheduled visit (Weeks 12 and 36 of each year 
of the Extension Phase); if this occurs then AE and concomitant medication checks will 
be performed in a documented telephone call.
6.4.4.
Physical Examination
The physical examination will be performed by a qualified physician at the times outlined 
in the Time and Events Table. At a minimum the following will be assessed: ear, nose 
and throat, cardiovascular system, pulmonary system, skin, abdomen and neurological 
system.
Body weight (kg) and height (meters) will be assessed at each physical examination. 
Patients will be weighed without shoes in light, indoor clothing. Height will be assessed 
with the patients shoes removed.  
6.4.5.
Pulmonary Assessment
The pulmonary assessments will be performed by trained site staff at the times outlined in 
the Time and Events Table.
Spirometry assessments (FEV1, FVC, PEF, MIP and MEP) should be performed in 
Cohorts 1 and 2 accordance with American Thoracic Society/European Respiratory 
Society guidelines. Predicted normal values will be calculated using local reference 
ranges. In Cohort 3 both these assessments and additional spirometry assessments (PCF 
and SNIP) should be performed. 
At all time points, three technically acceptable measurements should be made and 
recorded. All spirometry assessments should be made using the same make/model of 
spirometer throughout the study. 
Technically acceptable spirometry assessments should be repeatable i.e., values should 
YDU\ mL for both FEV1 and FVC readings. A minimum of three and a maximum of 
eight attempts may be made to provide the three reproducible readings. If repeatability 
has not been achieved after eight attempts, the highest value should be recorded (a 
technical comment should be made on the printout in such instances). The highest values 
for FEV1 and FVC may derive from different exhalation efforts.  

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 61 of 89
CONFIDENTIAL
The predicted values for spirometry assessments should be adjusted for age and sex. 
Assessments will be adjusted for race as shown in Table 1. 
Table 1
Adjustment of spirometry according to race
Race
Adjustment to predicted values
Caucasian
100%
All other races (including those of mixed race)
90%
Further information on performing spirometry assessments can be found in the Study 
Reference Manual.
6.4.6.
Laboratory Assessments
Please note Day 7 (Cohort 2 and 3 only), Week 4 (all cohorts) and Week 8 (Cohort 1 and 
2 only) assessments may be conducted by the sponsor-provided home nursing vendor. 
Patients who are enrolled in the Extension Phase may have home visits if only vitals and
blood samples are being collected at a scheduled visit; if this occurs then AE and 
concomitant medication checks will be performed in a documented telephone call.
6.4.6.1.
Haematology and Coagulation Times
Blood for the assessment of haematology parameters will be collected at the times 
outlined in the Time and Events Table. The following parameters will be assessed at each 
time point:
x
Haemoglobin
x
Haematocrit
x
Mean corpuscular volume 
x
White blood cells 
x
Red blood cells 
x
Neutrophils (percentage and absolute) 
x
Lymphocytes (percentage and absolute) 
x
Monocytes (percentage and absolute) 
x
Eosinophils (percentage and absolute) 
x
Basophils (percentage and absolute) 
x
Platelets

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 62 of 89
CONFIDENTIAL
Blood samples will be analysed centrally and samples will be maintained for 
confirmatory testing and then either destroyed or retained according to what the patient’s 
parents have consented. Further details on processing and shipping can be found in the 
laboratory and shipping manuals, respectively. 
6.4.6.2.
Clinical Chemistry
Blood for the assessment of serum chemistry parameters will be collected at the times 
outlined in the Time and Events Table. The following parameters will be assessed at each 
time point:
x
Total calcium
x
Potassium 
x
Sodium 
x
Albumin
x
Alkaline phosphatase  
x
Aspartate aminotransferase 
x
Alanine aminotransferase 
x
Gamma-glutamyl transferase
x
Bilirubin (total, direct and indirect)
x
Amylase
x
Lipase
x
Urea/BUN
x
Uric acid
x
Lactate dehydrogenase
x
Glutamate dehydrogenase
x
Creatine kinase
x
Creatinine
x
Fasting glucose
x
Fasting lipids
x
Cystatin C

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 63 of 89
CONFIDENTIAL
Additionally LFT, GLDH, amylase, lipase and coagulation parameters will be assessed 
on Day 7 in patients from Cohorts 2 and 3. 
Blood samples will be analysed centrally and samples will be maintained for 
confirmatory testing and then either destroyed or retained according to what the patient’s 
parents have consented. Further details on processing and shipping can be found in the 
laboratory and shipping manuals, respectively. 
6.4.6.3.
Additional Clinical Chemistry
Blood for the assessment of additional serum chemistry parameters (FGF-19 and C4) will 
be collected at the times outlined in the Time and Events Table. At screening and the end 
of study visit a single sample will be taken. At Week 1 two samples will be taken: pre-
AM dose and 3 h post AM dose. At Weeks 24 and 48 four samples will be taken: pre-AM 
dose, 3 h post AM dose, pre-PM dose and 4 h post PM dose.  
The following parameters will be assessed at each time point:
x
Fibroblast growth factor 19
x
&Į-hydroxy-4-cholesten-3-one) 
Blood samples will be analysed centrally and samples will be maintained for 
confirmatory testing and then either destroyed or retained according to what the patient’s 
parents have consented. As at least two central laboratories will be used for analysing 
these parameters blood should be collected into a minimum of two tubes. Further details 
on processing and shipping can be found in the laboratory and shipping manuals, 
respectively.
6.4.6.4.
Coagulation Parameters
Blood for the assessment of coagulation parameters will be collected at the times outlined 
in the Time and Events Table in Cohorts 2 and 3. The following parameters will be 
assessed at each time point:
x
Activated partial thromboplastin time
x
Prothrombin time
x
International normalised ratio
Blood samples will be analysed centrally and samples will be maintained for 
confirmatory testing and then either destroyed or retained according to what the patient’s 
parents have consented. Further details on processing and shipping can be found in the 
laboratory and shipping manuals, respectively. 

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 64 of 89
CONFIDENTIAL
6.4.6.5.
Urinalysis
Urine for the assessment of urinalysis parameters will be collected at the times outlined in 
the Time and Events Table. The following parameters will be assessed at each time point 
using a dipstick test:
x
Glucose 
x
Bilirubin
x
Ketones
x
Specific gravity
x
Blood 
x
pH 
x
Protein
x
Urobilinogen 
x
Nitrites
x
Leucocytes
Urine samples will be analysed locally using a dipstick and samples will be maintained 
for confirmatory testing and then either destroyed or retained according to what the 
patient’s parents have consented. If the following parameters have a result of ++ or 
higher, then a sample will be sent to the central laboratory for microscopic analysis: 
x
Glucose 
x
Bilirubin
x
Ketones
x
Blood 
x
Protein
x
Leucocytes
6.5.
Efficacy Procedures
If consent is given, the patient may be filmed during these procedures to enable study 
physicians to examine the patient’s movements.

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 65 of 89
CONFIDENTIAL
6.5.1.
North Star Ambulatory Assessment
The NSAA should be performed without shoes at the times outlined in the Time and 
Events Table.
Where possible this should be carried out by the same assessor in order to reduce 
variability. A copy of the instructions for patients and an example score sheet can be 
found in the Study Reference Manual. The order of the assessments is important and 
needs to be followed precisely. 
6.5.2.
10-Metre Run or Walk
The 10-metre run or walk should be performed at the times outlined in the Time and 
Events Table and as referenced in the Study Manual. 
A 10-metre straight course should be plotted out. Patients should be asked to complete 
the course as quickly as they can. Patients should start from immediately behind the start 
line and the time should start from the moment they cross the line until they reach 
10 meters. Patients should be asked to repeat the test after a 10 minute rest and both times 
will be recorded in the source documents and transcribed to the CRF. 
6.5.3.
Six-Minute Walk Distance
The 6MWD should be performed at the times outlined in the Time and Events Table and 
as referenced in the Study Manual. 
The 6MWD should be performed indoors in a flat, seldom used corridor at least 
30 meters in length. The length of the corridor should be marked every 3 meters. A cone 
(or equivalent) should be placed at the far end of the corridor to mark the turnaround spot 
and the start/stop line marked with another cone. Enough space should be allowed at each 
end of the corridor for the patient to turn around easily without bumping into anything. 
Patients should be instructed to walk as far as they can in 6 minutes by walking up and 
down the corridor remembering to go around the cone. If required they can stop to rest 
but should resume walking as soon as possible. They should be reminded that they need 
to walk not run along the course.
If patients do not produce two values where the second is within 20% of the first at 
screening then this procedure may be repeated once on a separate day as part of the same 
screening procedure.

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 66 of 89
CONFIDENTIAL
6.5.4.
Paediatric Outcomes Data Collection Instrument
The PODCI should be performed at the times outlined in the Time and Events Table. The 
patient’s parent or responsible adult should be given a copy of the questionnaire and 
asked to complete it. A copy of the questionnaire and scoring system can be found in the 
Study Reference Manual.
6.5.5.
Performance of the Upper Limb
The PUL assessment was specifically designed to assess upper limbs in patients with 
DMD [Mayhew, 2013]. The PUL should be performed at the times outlined in the Time 
and Events Table and BEFORE any biceps biopsy of patients. It consists of 21 items 
testing shoulder, elbow and distal upper limb performance reflecting functional tasks and 
a copy can be found in the Study Reference Manual.
7.
LIFESTYLE AND/OR DIETARY RESTRICTIONS
Patients must not use or consume any of the following throughout their involvement in 
the study: 
x
Cigarette smoke in the form of passive smoking where possible. They should 
not smoke cigarettes/e-cigarettes or any other source of nicotine (e.g., cigars, 
snuff, etc).  
x
Herbal supplements 
x
Daily intake of chargrilled meat above 250 grams/day 
x
Cruciferous vegetables above 150 grams/day 
8.
INVESTIGATIONAL MEDICINAL PRODUCT
8.1.
Dosage and Administration
Throughout the Treatment Phase all patients will receive SMT C1100 bid. Doses will be 
administered on an outpatient basis by their parent or responsible adult. There should be 
8–12 hours between the breakfast dose and evening meal dose.  
For boys in Cohorts 1 and 3, SMT C1100 will be administered, in the fed state, as the F3 
formulation and with a glass of whole/full-fat milk. A suitable number of syringes will be 
provided with the IMP and the volume prescribed will relate to the gradations on the 
measuring device. 
For boys in Cohort 2 SMT C1100 will be administered in a fed state with the F6 
formulation constituted in milk prior to immediate administration and followed by a 

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 67 of 89
CONFIDENTIAL
measure of milk to rinse the container. A suitable number of graduated dosing cups will 
be provided with the IMP. The Treatment Phase for all Cohorts in the main study will last 
48 weeks. The Extension Phase will extend until drug approval/discontinuation. 
8.1.1.
Dose Modification Guidelines
The Investigator should determine if each SAE is related to study drug. Serious AEs 
considered at least possibly related to study drug may require a dose reduction after 
discussion with the Sponsor, a temporary hold, or permanent discontinuation. 
8.2. 
Dose Rationale 
Lower than expected SMT C1100 exposure levels were observed in the first clinical 
study (SMT C11002) using an aqueous microfluidised suspension F2. Further analysis of 
the data from the study identified the importance of diet and fat intake. Clinical study 
SMT C11003 using the microfluidised formulation (F3) with an appropriate diet plus the 
immediate consumption of full fat milk after the dose increased SMT C1100 plasma 
exposure to levels believed to be able to modulate the utrophin mechanism (based on 
EC50 data in primary human myotubes). In parallel, additional formulation development 
work was undertaken with the aim of increasing further the systemic exposure to SMT 
C1100 in DMD patients. Results in a 7-day rat study (N-109) showed that two new 
formulations (F6, a powder for oral suspension and F5, a nanosuspension) gave higher 
exposure levels to SMT C1100 with no significant change in the ratio of parent to DHD I 
and DHD III when compared to the F3 microfluidised suspension. There was a relative 
increase in exposure of three-fold and two-fold seen with the F6 and F5 formulations, 
respectively, in the rat.
In study SMT C11002, maximum exposure was seen at the 100 mg/kg bid dose which 
supported a fixed dose of 2.5 g bid in a Duchenne patient with a projected lean body mass 
(LBM) of 25 kg (Griffiths et al 1988). Thus a fixed escalating dose of 1.25 g bid and then 
2.5 g bid was used in the SMT C11003 study with the F3 formulation. Based on the 
higher rat exposure for the newer formulations relative to F3, the starting dose of the F6 
powder for oral suspension and F5 nanosuspension formulations in SMT C11004 study 
Part A (healthy adult subjects with a projected LBM of 60 kg) were lowered accordingly 
(three-fold for the F6 formulation [~32 mg/kg] and two-fold for the F5 formulation 
[~50 mg/kg]) to achieve an approximate exposure equivalence to the 2.5 g dose for the 
F3 formulation in SMT C11003. Consequently the doses selected for investigation in 
SMT C11004 Part A were 2 g bid and 4 g bid for the F6 formulation and 3 g bid and 6 g 
bid for the F5 formulation. As shown in the top half of Table 1, the F6 formulation in 
healthy volunteers gave approximately two- to three-fold higher exposure than F5 when 
comparing the dose normalized Cmax and AUC values, respectively. As the F6 
formulation showed a more than 10-fold increase in exposure (AUC) compared to the F3 

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 68 of 89
CONFIDENTIAL
formulation in the normal healthy subjects, a starting dose of 0.25 g bid for the F6 
formulation was chosen for the first 7-day dosing period with the goal of achieving a 
similar SMT C1100 exposure to the current 2.5 g bid F3 formulation. Subsequent dose 
escalations were to 0.5 g bid for 7 days and 1 g bid for 7 days. Using the Geometric mean 
Cmax for F6 formulation of 389 ng/mL, the Cmax concentration in DMD patients was >6 
fold higher than observed with the F3 formulation at these doses, as shown in the bottom 
half of Table 1. 
Table 1 – SMT C1100 exposure (Geometric means) comparison across three 
formulations 
Study
Subject
a
Formulationb
Dose 
Level 
(bid) 
Dayc
Cmax
(ng/mL)
Dose 
Normalised 
Cmaxd
AUC
(ng*h/mL)
Dose 
Normalised 
AUCd
SMTC11004
HV
F5
3 g
3
389
130
2681
984
SMTC11004
HV
F6
2 g 
3
746
373
3870
1935
SMTC11003
DMD
F3
2.5 g 
14
61
25
350
140
SMTC11004
DMD
F6
1 g
7
416
416
3855e
1928
a HV – Healthy volunteer; DMD – Patient
b F3 – Microfluidised aqueous oral suspension; F5 – Aqueous oral nanosuspension; F6 – powder for oral suspension
c Day Cmax and AUC was obtained which was the last day of dosing at the respective dose level 
d Cmax and AUC value normalised to 1 g
e All AUC’s are 0–12 h except for DMD patients with F6 which is AUC 0–24 h. Based on bid dosing, the corresponding 
dose level was used for dose normalisation (g/bid dose for 0–12 h and g/day for 0–24 h) 
SMT C1100 given as the F6 formulation was found to be generally safe and well 
tolerated at doses up to 1 g bid given for 7 days in the DMD subjects (Study SMT 
C11004). Adverse events were seen across all doses but no increase with dose could be 
discerned. The majority of the AEs were gastrointestinal in nature with diarrhoea being 
the most frequently reported event. All but one of the AEs were mild or moderate in 
nature. There was one serious (severe) AE of elevated liver function test abnormalities 
with the 0.25 g bid dose, the cause of which is unknown (CIOMS SMT2016GB000034). 
The patient himself was clinically well but nevertheless discontinued from the study after 
a positive rechallenge with 0.25 g bid in Part B, Period 2. The patient’s laboratory values
were within the normal range at the 2-week follow-up visit. One additional subject 
discontinued on Day 7 after his AM dose in the 1 g bid dose period for an AE of 
abdominal pain.  

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 69 of 89
CONFIDENTIAL
The potential of SMT C1100 to induce utrophin modulation in primary human skeletal 
muscle cells (myotubes) was assessed in the utrophin induction assay (Study No. N-058). 
SMT C1100 was shown to trigger utrophin protein modulation in a dose-dependent 
manner with a maximal 1.45-fold increase and the EC50 was determined to be 205 nM 
(67 ng/mL). In SMT C11004 Part B, at the two highest dose levels, mean (geometric) 
SMT C1100 Cmax was > 70 ng/mL, with the highest geometric mean Cmax over 24 hours 
being 390 ng/mL at the 1 g bid dose level at steady state (Day 7). In study N-115, DHD 
III has also shown potential to modulate utrophin transcription in the H2K cell reporter 
assay with 6-fold lower potency (EC50 ~4.5μM) compared to SMT C1100. Thus the 
relatively high levels of DHD III metabolite (mean Cmax of 14 μM at steady state) may 
provide a meaningful contribution to pharmacology. DHD I was much less potent in the 
reporter assay- 30-fold lower than SMT C1100 - and plasma exposure is also lower than 
DHD III so the DHD I metabolite is less likely to play a key role in pharmacology. 
In Study SMT C11004, overall there was an increase in steady state SMT C1100 Cmax
and AUC0–24 with increasing dose which was greater than dose proportional at doses of 
0.5 g bid and 1 g bid for 7 days. There was little to no accumulation of SMT C1100 with 
repeated dosing. There was dose proportionality between the 0.25 g bid and 0.5 g bid
dose levels. The F6 powder for oral suspension at a dose of 1 g bid achieved a greater 
than six-fold increase in maximum SMT C1100 plasma levels (14-fold if comparing dose 
normalised data) in DMD patients compared to those achieved with the current clinical 
formulation, F3, and consequently this formulation and dose will be investigated in a 
small number of patients in Study SMT C11005. 
Chronic nonclinical toxicology studies provide up to 14-fold exposure multiple to SMT 
C1100 compared to 1 g bid in DMD patients using the F6 formulation. This includes 
26 weeks of dosing in rodent (rat and mouse) and 39 weeks of dosing in non-rodent 
(minipig). No adverse findings were observed in these nonclinical studies up to the limit 
dose. Exposure to DHD I was also two- to three-fold higher (based on total or free DHD I 
levels, respectively) in rats on the 26 week toxicology study versus F6 in DMD patients. 
Patient exposure to DHD III using the F6 formulation is approximately four-fold higher 
than observed in nonclinical toxicology studies, or less than two-fold higher based on 
calculated free DHD III levels, although rat DHD III levels were underestimated 
approximately 40% by the calculation method that was used. However, despite the lack 
of nonclinical toxicology coverage of DHD III, this metabolite is not considered to have 
any unique safety risks based on in vitro and in silico assessments relative to SMT C1100 
or DHD I (see below). Additionally, DHD III may be pharmacologically active given the 
ability to modulate utrophin transcription in the H2K cell reporter assays. A number of 
potential off-target effects have been identified for SMT C1100, DHD I, and DHD III 
based on a battery of in vitro assays. However, the majority of these off-target effects had 
in vitro IC50values that are above the total or calculated free levels at the highest patient 
exposure level (1 g bid with the F6 formulation). Additionally, there were no associated 

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 70 of 89
CONFIDENTIAL
in vivo findings from chronic toxicology studies and 7 days dosing in patients at three 
dose levels up to 2 g/day. A possible exception could be inhibition of the OATP1B1 
transporter by DHD I and III which may have contributed to elevated conjugated 
bilirubin observed in one patient.  Other potential safety risks such as inhibition of BCRP, 
and MAO-B as well as induction/inhibition of CYP2B6 have been addressed by 
excluding the respective substrates as co-medications during SMT C1100 administration. 
Potential inhibition of hERG and Cav1.2 by DHD I and III have not corresponded to any 
arrhythmias from nonclinical safety pharmacology studies nor were there ECG findings 
in patients. If the dihydrodiols are potent inhibitors in vivo, it’s possible that inhibition of 
both cardiac ion channels has an off-setting effect counteracting any torsadogenic effect 
[Kramer et al, 2013] as may occur with verapamil. Overall, the risk:benefit of using the 
F6 formulation to increase exposure to SMT C1100 and thus increase the probability of 
achieving sufficient utrophin levels to have a beneficial effect in DMD patients is 
considered favourable.   
8.3. 
Blinding 
This is an open-label study so no blinding is required. 
8.4. 
Packaging and Labelling 
Investigational medicinal product will be supplied to the sites in multi-dose bottles for the 
F3 formulation (Cohorts 1 and 3) and as unit doses for the F6 formulation (Cohort 2). 
The sites will dispense appropriate numbers of bottles to the parent/responsible adult who 
will be undertaking the outpatient dosing activities. Written instructions will be provided 
for the parent including the exact dose that should be given and instructions for 
preparation and storage. Where required, appropriate measuring devices (e.g., syringes) 
will be provided to the parent/responsible adult to ensure that they can give an accurate 
dose. New medication bottles should be issued at each study visit, and used bottles should 
be returned and collected for reconciliation.
In an effort to manage the adversity of site visits for patients, IMP and ancillary supplies 
may be shipped directly to the subject’s residence at regular intervals, as required and 
based on available inventory, for the duration of the Treatment and Extension Periods. 
This will only be undertaken following approval from the IEC/IRB, Investigator and 
patient parent/guardian. All used and unused IMP will be returned to the site or central 
drug depot, as applicable, for the purposes of drug accountability. 
Investigational product labels will contain all information required to meet the local 
applicable regulatory requirements.

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 71 of 89
CONFIDENTIAL
8.5. 
Preparation 
No additional preparation of the microfluidised aqueous suspension (F3) is required after 
dispensing. The powder for oral suspension (F6) requires constitution in vehicle ahead of 
dosing. Written instructions will be provided for the parent/responsible adult to prepare 
and administer the dose. 
8.6. 
Handling and Storage 
The F3 formulation (Cohorts 1 and 3) will be stored at site at room temperature (<25ºC) 
and protected from light. The parent/responsible adult looking after the IMP for 
outpatient dosing will be asked to keep it at room temperature (<25ºC) and protected 
from light. The IMP should be kept out of the reach of children. 
The F6 formulation (Cohort 2) will be stored at site at refrigerated temperature (2-8ºC). 
The parent/responsible adult looking after the IMP for outpatient dosing will be asked to 
keep it at refrigerated temperature (2–8ºC). The IMP should be kept out of reach of 
children. 
No special procedures for the safe handling of SMT C1100 are required. The Sponsor 
will be permitted, upon request, to audit the supplies, storage, dispensing procedures and 
records at each site.
8.7.
Product Accountability and Assessment of Compliance 
In accordance with GCP, each study centre will account for all supplies of SMT C1100 
provided to them. Details of receipt, storage, assembly and return will be recorded. The 
unit of accountability will be one bottle of SMT C1100. 
All unused supplies of SMT C1100 will either be destroyed or returned to the study 
Sponsor at the end of the study in accordance with instruction by the Sponsor. 
3DWLHQWVZLOOEHFRXQWHGDVFRPSOLDQWZLWKWKHSURWRFROLIWKH\WDNHRItheir 
medication as scheduled.
8.8. 
Treatment of Investigational Product Overdose 
If the patient receives an overdose of the IMP (classed as having >2.5 g of SMT C1100 
F3 in Cohorts 1 and 3 or >1 g of SMT C1100 F6 in Cohort 2 in a 4 hour period) then the 
Investigator should be notified as soon as possible. 
The Investigator will treat the overdose according to their clinical judgment depending on 
the extent of the overdose and the clinical signs and symptoms exhibited by the patient. It 

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 72 of 89
CONFIDENTIAL
should be noted that drug-related AEs of pale and/or discoloured stools have been 
reported in clinical trials to date. These AEs have been reported at doses of 1.25 g bid and 
2.5 g bid with SMT C1100 F3 in a 14-day DMD patient study and at doses of 0.5 g bid
with SMT C1100 F6 in a 7-day DMD patient study. The AEs were possibly a 
consequence of a greater proportion of unabsorbed study drug passing through the 
gastrointestinal tract at higher dose levels. Changes in liver function tests were also noted 
at doses of 0.25–1 g bid with F6 in the 7-day DMD patient study. 
The Sponsor and Quintiles pharmacovigilance should be informed in writing of all 
overdoses within 24 hours of the Investigator becoming aware of them. 
8.9.
Occupational Safety
No specific risks have been identified for staff handling SMT C1100. The Material Safety 
Data Sheet will be made available where required by local regulations.
9.
CONCOMITANT MEDICATIONS AND NON-DRUG 
THERAPIES 
9.1. 
Permitted Medications 
Permitted medications include the following:
x
Systemic corticosteroids (required for 6 months prior to study entry with stable dose 
[intermittent dosing is allowed] for at least 6 months prior to start of trial), including 
but not limited to, prednisolone, prednisone and deflazacort 
x
Angiotensin converting enzyme inhibitors (e.g., perindopril and lisinopril) 
x
Angiotensin-receptor blockers (e.g., losartan, irbestartan, valsatan and candesartan)
x
Bisphosphonates (oral and intravenous), Vitamin D and calcium supplements 
Investigators should use caution when concomitantly administering SMT C1100 and 
drugs that are substrates of OATP1B1 and/or OATP1B3 e.g., angiotensin-converting 
enzyme inhibitors, and angiotensin II receptor antagonists. They should monitor patients 
closely for signs and symptoms of excessive exposure to the drugs that are substrates of 
OATP1B1/1B3 and consider reduction of the dose of these drugs.  
9.2. 
Prohibited Medications 
Use of the following therapies is prohibited during the study and for at least five half-
lives prior to the start of dose administration, unless otherwise stated below:

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 73 of 89
CONFIDENTIAL
x
Substrates of CYP2B6 e.g., Ketamine, Pentobarbitol, Lidocaine (see Appendix 1 for 
further details), except as used for anaesthesia during the study-required biopsy in a 
hospital setting.
x
Inducers of CYP1A1 and/or CYP1A2 e.g., Omeprazole, Carbamazepine, Rifampin 
(see Appendix 1 for further details) 
x
Nicotine, including exposure to daily passive smoking (including parent/legal 
guardian, siblings) to minimise CYP1A induction 
x
Herbal supplements and homeopathic preparations should be stopped 7 days prior to 
the start of the Treatment Phase
x
Substrates of BRCP (e.g., omeprazole, rabeprazole, fluvastatin, methotrexate, 
mitoxantrone, imatinib, irinotecan, lapatinib, rosuvastatin, sulfasalazine, topotecan) 
x
Beta-blockers (these may be started during the study if required but patients must not 
be enrolled whilst taking them)
x
All prescription, OTC, and herbal products that are known CYP2B6 sensitive 
substrates (e.g., buproprion, efavirenz) will be excluded from 14 days prior to study 
conduct through to 14 days after study conduct completion. Please note, this is not an 
exhaustive list of CYP2B6 substrates and a discussion with the medical monitor may 
be warranted. Further details of CYP2B6 substrates are found in Appendix 1.  
x
Be using drugs that have serotonergic, norepinephrinergic or dopaminergic activity 
(e.g., selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake 
inhibitors, tricyclic antidepressants, tryptophan, dextromethorphan, meperidine, 
bupropion, nortriptyline, desipramine, doxepin, amoxapine, rasagiline, selegiline), or 
treatments used in attention deficit hyperactivity disorder such as Methylphenidate, 
and phenethylamine (PEA). 
In the interests of patient safety and acceptable standards of medical care the Investigator 
will be permitted to prescribe treatment(s) at his/her discretion. All treatments must be 
recorded in the patient’s source documents and transcribed to the CRF (medication, dose, 
treatment duration and indication). 
10.
PATIENT COMPLETION AND WITHDRAWAL
10.1.
Patient Completion 
A patient will be classed as having completed the study at the end of the 30-day Safety 
Follow-Up unless they are rolled into the Extension Phase. 

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 74 of 89
CONFIDENTIAL
10.2.
Patient Withdrawal
10.2.1.
Patient Withdrawal from Investigational Medicinal Product
A patient will be withdrawn from treatment for any of the following reasons: 
x
Withdrawal of consent/assent to continue taking treatment 
x
The study Investigator or Sponsor, for any reason, decides the patient should be 
withdrawn from the treatment 
x
Adverse events, classed as possibly or probably related by the Investigator, which 
cannot be tolerated by the patient
If a patient is withdrawn from treatment where possible they should continue to attend all 
remaining study visits so that data can be collected. If patients will not assent or their 
parents/guardian will not consent to this then they should be withdrawn from the study. 
10.2.2.
Patient Withdrawal from Study
A patient will be withdrawn from the study for any of the following reasons: 
x
Lost to follow-up 
x
Withdrawal of consent/assent 
x
Patient is not in compliance with requirements of the study
x
Death
x
The study Investigator or Sponsor, for any reason, decides the patient should be 
withdrawn from the study 
x
The study Investigator or Sponsor, for any reason, stops the study 
If a patient is lost to follow-up, every possible effort must be made by the study centre 
personnel to contact the patient and determine the reason for discontinuation. The 
measures taken to follow-up must be documented. 
When a patient withdraws before completing the study, the reason for withdrawal is to be 
documented in the source documents and transcribed to the CRF. Study drug assigned to 
the withdrawn patient may not be assigned to another patient.  
Where possible any patient that withdraws from the study will complete the Early 
Termination Visit as outlined in the Time and Events Table.

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 75 of 89
CONFIDENTIAL
10.3. 
Treatment after the End of the Study 
No IMP will be provided after the end of the Treatment Phase unless the subject 
continues into the Extension Phase.  
10.4.
Screen and Baseline Failures
Data collected from screening failures will be limited to reason for screen failure and 
related data.
11.
ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS  
11.1.
Adverse Events
An AE is any untoward medical occurrence in a patient or clinical investigation patient 
administered a pharmaceutical product and which does not necessarily have a causal 
relationship with this treatment. An AE can therefore be any unfavourable and 
unintended sign (including an abnormal laboratory finding), symptom, or disease 
temporally associated with the use of a medicinal (investigational) product, whether or 
not related to the medicinal (investigational) product.
Adverse events will be recorded from the signing of the consent form until the end of the 
safety follow-up period or completion of the Extension Phase. 
11.1.1.
Causal Relationship
Causal relationship assessment to drug treatments is required for purposes of reporting 
AEs. To promote consistency, the following guidelines should be taken into 
consideration along with good clinical and scientific judgment when determining the 
relationship of drug treatments to an AE: 
x
Probable relationship: event occurs in a plausible time relationship to the medication 
administration and cannot be explained by concurrent disease or other drugs or 
chemicals; the response to the withdrawal of the drug should be clinically plausible 
x
Possible relationship: event occurs with a reasonable time sequence to the 
medication administration, but could also be explained by concurrent disease or 
other drugs or chemicals; information on the drug withdrawal may be lacking or 
unclear
x
Unlikely relationship: event occurs with little temporal relationship to the medication 
administration and other factors such as drugs, chemicals or underlying disease 
provide plausible explanations 

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 76 of 89
CONFIDENTIAL
x
Not related: event has no temporal relationship to the medication administration or 
there is a definite alternative aetiology
11.1.2.
Severity Criteria
An assessment of severity grade will be made using the following general categorical 
descriptors: 
x
Mild: awareness of symptoms that are easily tolerated causing minimal discomfort 
and not interfering with everyday activities
x
Moderate: sufficient discomfort is present to cause interference with normal activity
x
Severe: extreme distress causing significant impairment of functioning or 
incapacitation. Prevents normal, everyday activities
The Investigator should use clinical judgment in assessing the severity of events not 
directly experienced by the patient (e.g., laboratory abnormalities).
11.1.3.
Reporting Adverse Events
All AEs and special reporting situations, whether serious or non-serious, will be reported 
from the time a signed and dated informed consent form is obtained until completion of 
the patient's last study-related procedure (which may include contact for follow-up of 
safety). The Sponsor will evaluate any safety information that is spontaneously reported 
by an Investigator beyond the time frame specified in the protocol. 
All AEs, regardless of seriousness, severity, or presumed relationship to study therapy, 
must be recorded using medical terminology in the source document and the CRF. 
Whenever possible, diagnoses should be given when signs and symptoms are due to a 
common aetiology (e.g., cough, runny nose, sneezing, sore throat, and head congestion 
should be reported as "upper respiratory infection"). Investigators must record in the 
source documents and the CRF their opinion concerning the relationship of the AE to 
study therapy. All measures required for AE management must be recorded in the source 
document and reported according to Sponsor instructions. 
The patient’s parents or responsible adult must be provided, on Day 1, with a "study 
card" indicating the following:
x
Patient's name
x
Patient number 
x
Patient's data of birth
x
Name of the investigational product 

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 77 of 89
CONFIDENTIAL
x
Investigator's name and 24 hour contact information 
x
Statement that the patient is participating in a clinical trial
11.2. 
Serious Adverse Events 
A serious AE (SAE) is any untoward medical occurrence that at any dose:  
x
Results in death
x
Is life-threatening
x
Requires inpatient hospitalisation or prolongation of existing hospitalisation 
x
Results in persistent or significant disability/incapacity
or 
x
Is a congenital anomaly/birth defect
Medical and scientific judgment should be exercised in deciding whether reporting is 
appropriate in other situations, such as important medical events that may not reach the 
above definition but may jeopardise the patient or may require medical or surgical 
intervention to prevent one of the other outcomes listed in the above definition. These 
should also be considered serious. Examples of such events are invasive or malignant 
cancers, intensive treatment in an accident and emergency department or at home for 
allergic bronchospasm, blood dyscrasias or convulsions that do not result in 
hospitalisation, or development of drug dependency or drug abuse. 
Serious AEs will be recorded from the signing of the consent form until the end of the 
safety follow-up period. 
11.2.1.
Suspected Unexpected Serious Adverse Reactions
Suspected unexpected serious adverse reactions (SUSARs) are AEs that are believed to 
be related to an IMP and are both unexpected (i.e., the nature or severity is not expected 
from the information provided in the Investigator’s Brochure) and serious. 
11.2.2.
Reporting Serious Adverse Events
All SAEs occurring during clinical studies must be reported to the appropriate Sponsor-
designated contact person by investigational staff within 24 hours of their knowledge of 
the event.
Information regarding SAEs will be transmitted to Quintiles using the Serious Adverse 
Event Form, which must be completed and signed by a member of the investigational 

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 78 of 89
CONFIDENTIAL
staff, and transmitted to Quintiles pharmacovigilance within 24 hours. The initial and 
follow-up reports of an SAE should be sent to one of the following: 
Quintiles Drug Safety Fax (EAPA): 0 800 132 079 
Quintiles Drug Safety Fax (NA): 1 800 41 48 460 
Quintiles Drug Safety Centre Email: QLS_SMTC1100@quintiles.com
All SAEs that have not resolved by the end of the study, or that have not resolved upon 
discontinuation of the patient's participation in the study, must be followed until any of 
the following occurs: 
x
The event resolves
x
The event stabilises
x
The event returns to baseline, if a baseline value/status is available
x
The event can be attributed to agents other than the study drug or to factors unrelated 
to study conduct 
x
It becomes unlikely that any additional information can be obtained (patient or health 
care practitioner refusal to provide additional information, lost to follow-up after 
demonstration of due diligence with follow-up efforts)
Any event requiring hospitalisation (or prolongation of hospitalisation) that occurs during 
the course of a patient's participation in a clinical study must be reported as an SAE, 
except hospitalisations for the following: 
x
Surgery or procedure planned before entry into the study (must be documented in the 
source documents and CRF) 
The cause of death of a patient in a clinical study within 30 days of last dose, whether or 
not the event is expected or associated with the investigational agent, is considered a 
SAE.
The Sponsor or designee assumes responsibility for appropriate reporting of AEs to the 
regulatory authorities. The Sponsor (or designee) will also report to the Investigator all 
SAEs that are SUSARs (unexpected) and associated with the use of the drug. The 
Investigator (or Sponsor where required) must report these events to the appropriate 
Independent Ethics Committee (IEC)/Institutional Review Board (IRB) that approved the 
protocol unless otherwise required and documented by the IEC/IRB. 

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 79 of 89
CONFIDENTIAL
12.
DATA ANALYSIS AND STATISTICAL CONSIDERATIONS
Before the study database is locked a statistical analysis plan will be finalised providing 
detailed methods for the analyses outlined below. 
12.1. 
Data Analysis Considerations 
12.1.1.
Analysis Populations
The ‘Safety’ and ‘Intent-To-Treat (ITT)’ populations will both be defined as all patients 
who receive at least one dose of study medication. 
Separate populations will be identified for MRI and functional activity endpoints, based 
upon their baseline ability to be assessed for the relevant endpoint. Further information 
on these populations will be provided in the Statistical Analysis Plan. 
12.1.2.
Treatment Comparisons
Though the study includes a single treatment group, comparisons will be made with SMT 
C1100 plasma exposure and MRI parameters and other endpoints through concentration 
response analyses. Similarly, the relationship between utrophin expression and other 
endpoints will be explored. 
12.1.3.
Interim Analysis
A DMC will review the study data throughout the study (Section 13.2). As the study is 
open-label the data will also be explored on a regular basis by the Sponsor. 
12.1.4.
Key Elements of Analysis Plan
Where appropriate the data from the different cohorts will be pooled for analyses. 
Baseline characteristics will be summarised for each cohort separately and over all
patients.
Changes from baseline in primary and secondary endpoints will be summarised and 
plotted by visit, as will blood biomarker data and pharmacokinetic data. In addition to 
descriptive statistics (n, mean, standard deviation, median, minimum and maximum) data 
will be summarised categorically through the count of patients with specific levels of 
improvement or deterioration from baseline with the different endpoints. 
Data for sub-groups based on baseline characteristics, SMT C1100 concentrations and 
utrophin expression will also be summarised. 

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 80 of 89
CONFIDENTIAL
If possible, changes from baseline may be compared with historical control data. 
12.1.4.1.
Pharmacodynamic Analyses
All pharmacodynamic endpoints will be summarised. 
The relationship between MRI parameters (leg MRI for Cohorts 1 and 2 and cardiac MRI 
for Cohort 3) over time and SMT C1100 exposure will be investigated along with 
relationship of other endpoints (including changes in utrophin expression) and SMT 
C1100 exposure over time. Similarly, the relationship between changes in utrophin 
expression and MRI parameters will be investigated. 
12.1.4.2.
Pharmacokinetic Analyses
Plasma concentrations of SMT C1100 parent and metabolites will be summarised and 
plotted by time point. Using a model exposure parameters will be predicted for each 
subject at the relevant visits. These parameters will be used as the exposure parameters 
when investigating the relationships with other data. 
Data will be summarised for each cohort separately, combining Cohorts 1 and 3 (F3 
formulation), and over all patients.
12.1.4.3.
Safety Analyses
Adverse events will be summarised by system organ class and preferred term using the 
Medical Dictionary for Regulatory Activities. The frequency and percentage of patients 
will be tabulated for each of the following: 
x
All causality AEs
x
Treatment-related (possibly or likely related to study drug) AEs 
x
Intensity (mild/moderate/severe) of AEs
x
Serious AEs 
x
Adverse events leading to study drug discontinuation 
Changes from baseline in laboratory assessments, vital signs measurements, pulmonary 
function parameters (including FEV and FVC) and ECG parameters will be summarised. 
The relationship between safety endpoints and SMT C1100 parent and metabolite 
exposure may also be investigated. 

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 81 of 89
CONFIDENTIAL
12.1.4.4.
Efficacy Analyses
All activity endpoints will be summarised.  
The relationship between changes from baseline over time and SMT C1100 exposure will 
be investigated.  
12.1.5.
Missing, Unused and Spurious Data
Missing data will be accounted for in all summaries by time, with reasons provided 
where possible (e.g., discontinuation). If any data are excluded from analyses the reason 
for their exclusion will be documented in the clinical study report. 
12.1.6.
Reporting Deviations from the Statistical Plan
Any deviations from the planned analyses will be described and justified in the final 
clinical study report.
13.
STUDY ADMINISTRATION
13.1. 
Regulatory and Ethical Considerations, Including the 
Informed Consent Process 
Prior to initiation of a study site, the Sponsor will obtain approval from the appropriate 
regulatory agency to conduct the study in accordance with the ICH GCP and applicable 
country-specific regulatory requirements.
The study will be conducted in accordance with all applicable regulatory requirements.
The study will be conducted in accordance with ICH GCP, all applicable patient privacy 
requirements and the ethical principles that are outlined in the Declaration of Helsinki 
2013, including, but not limited to: 
x
Institutional review board review and approval of study protocol and any subsequent 
amendments
x
Patient informed consent 
x
Investigator reporting requirements
The Sponsor will provide full details of the above procedures, either verbally, in writing, 
or both. 
Written informed consent and assent must be obtained from each patient (and their 
parents/guardian) prior to participation in the study. Written informed consent will be 

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 82 of 89
CONFIDENTIAL
collected following a review of the patient’s information leaflet by the potential patient 
and their parents/guardian and a discussion between the patient and their parents/guardian 
and the Investigator or suitably-qualified designee. 
The Investigator will cooperate with all regulatory inspections and will notify the 
Sponsor as soon as they are aware of an inspection which may involve this study. With 
the exception of statutory regulatory authority inspections, the Sponsor will be consulted 
in the event of inspection of the clinical site(s) by an outside authority before the 
Inspectors are permitted access to any of the study records or the study areas.
13.2. 
Data Monitoring Committee 
While the study is in progress, a DMC will conduct planned reviews of the study data to 
evaluate the safety and tolerability of the study drug treatment.
A DMC charter defining the objectives and operational details of the DMC (including 
timing of meetings) has been finalised prior and further changes will be version 
controlled. 
13.3. 
Study Monitoring 
In accordance with applicable regulations, GCP and the Sponsor’s and/or delegate 
procedures, monitors will contact the site prior to the start of the study to review with the 
site staff the protocol, study requirements, and their responsibilities to satisfy regulatory, 
ethical, and the Sponsor’s requirements. When reviewing data collection procedures, the 
discussion will include identification, agreement and documentation of source 
documents. 
The Sponsor and or delegated monitors will visit each trial site during the conduct of the 
study to ensure that: 
x
The data are authentic, accurate and complete
x
The patient’s safety and rights are being protected
x
The study is conducted in accordance with the currently approved protocol and any 
other study agreements, GCP and all applicable regulatory requirements 
13.3.1.
Access to Source Data
The Investigator and the head of the medical institution (where applicable) agrees to 
allow the monitor, Sponsor-appointed auditors and regulatory inspectors direct access to 
all relevant documents.

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 83 of 89
CONFIDENTIAL
13.3.2.
Data Handling and Record Keeping
Following closure of the study, the Investigator or head of the medical institution (where 
applicable) must maintain all site study records (except for those required by local 
regulations to be maintained elsewhere) in a safe and secure location. The records must 
be easily accessible when needed (e.g., for a Sponsor audit or regulatory inspection) and 
must be available for review in conjunction with assessment of the facility, supporting 
systems, and relevant site staff.
Where permitted by local laws/regulations or institutional policy, some or all of the 
records may be maintained in a format other than hard copy (e.g., microfiche, scanned, 
electronic); however, caution must be exercised before such action is taken. The 
Investigator must ensure that all reproductions are legible and are a true and accurate 
copy of the original. In addition, they must meet accessibility and retrieval standards, 
including regeneration of a hard copy, if required. The Investigator must also ensure that 
an acceptable back-up of the reproductions exists and that there is an acceptable quality 
control procedure in place for creating the reproductions. 
The Sponsor will inform the Investigator of the time period for retaining the site records 
in order to comply with all applicable regulatory requirements. The minimum retention 
time will meet the strictest standard applicable to a particular site, as dictated by local 
laws/regulations, the Sponsor standard operating procedures (SOPs), and/or institutional 
requirements.
The Investigator must notify the Sponsor of any changes in the archival arrangements, 
including, but not limited to archival of records at an off-site facility or transfer of 
ownership of the records in the event that the Investigator is no longer associated with the 
site.
13.4. 
Provision of Study Results and Information to Investigators 
Where required by applicable regulatory requirements, an Investigator signatory will be 
identified for the approval of the clinical study report. The Investigator will be provided 
reasonable access to statistical tables, figures and relevant reports and will have the 
opportunity to review the complete study results at a mutually agreeable location. 
The Sponsor will also provide the Investigator with the full summary of the study results. 
The Investigator is encouraged to share the summary results with the study patients, as 
appropriate. 
The study will be registered automatically in the EU Clinical Trials Register and a results 
summary will be posted to the Register no later than 12 months after the last patient last 

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 84 of 89
CONFIDENTIAL
visit (LSLV). In addition, the study will be posted on ClinicalTrials.gov and the results 
will be uploaded no later than 12 months after LSLV. 
13.5. 
Confidentiality of Study Patients  
All information obtained during the conduct of the study with respect to the patient will 
be regarded as confidential and confidentiality of all patients will be maintained. 
Monitors, auditors and inspectors will require access to a patient’s medical notes for the 
purpose of source document verification but the patient’s confidentiality will be 
maintained at all times. An agreement for disclosure of any such information will be 
obtained in writing and is included in the statement of informed consent. 
The study data shall not be disclosed to a third party without the written consent of the 
Sponsor. All data shall be secured against unauthorised access.
The Investigator will maintain a list of patient names and identifying information (e.g., 
unique patient identification number, patient’s hospital number, patient randomisation 
number). This list will not be collected by the Sponsor. 
13.6. 
Data Management 
For this study patient data will be collected using a CRF and combined with data 
provided from other sources in a validated data system. 
Management of clinical data will be performed in accordance with the applicable Sponsor 
or designee standards and data cleaning procedures to ensure the integrity of the data, 
e.g., removing errors and inconsistencies in the data. Adverse events and concomitant 
medications terms will be coded using the Medical Dictionary for Regulatory Activities 
and WHODrug. 
When using electronic trial data handling and/or remote electronic trial data systems, the 
Sponsor or designee will:  
a.
Ensure and document that the electronic data processing system(s) conforms to the 
Sponsor’s established requirements for completeness, accuracy, reliability, and 
consistent intended performance (i.e., validation). 
b.
Maintain SOPs for using these systems. 
c.
Ensure that the systems are designed to permit data changes in such a way that the 
data changes are documented and that there is no deletion of entered data (i.e., 
maintain an audit trail, data trail, edit trail).
d.
Maintain a security system that prevents unauthorised access to the data.

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 85 of 89
CONFIDENTIAL
e.
Maintain a list of the individuals who are authorised to make data changes.
f.
Maintain adequate backup of the data.
g.
Safeguard the blinding, if any (e.g., maintain the blinding during data entry and 
processing).
Training on the use of the electronic data collection system will be provided to all 
relevant study site staff.
13.7. 
Insurance, Indemnity and Finance 
The Sponsor maintains appropriate insurance coverage for clinical studies and will follow 
applicable local compensation laws.
The Sponsor will indemnify all Investigators participating in this study against future 
claims by study participants the terms of this will be detailed within a separate letter of 
indemnification. The indemnity will only apply where all study procedures have been 
carried out according to this protocol. 
The financial aspects of the study are addressed in a separate agreement.

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 86 of 89
CONFIDENTIAL
14.
REFERENCES
Anthony K, Cirak S, Torelli S, et al. '\VWURSKLQTXDQWL¿FDWLRQDQGFOLQLFDOFRUUHODWLRQVLQ
Becker muscular dystrophy: implications for clinical trials; Brain 2011: 134; 3544–3556.
Arpan I, Willcocks R, Forbes S et al. Examination of effects of corticosteroids on skeletal 
muscles of boys with DMD using MRI and MRS. Neurology 2014;83:974–980. 
Bogdanovich S, Krag TO, Barton ER, et al. Functional improvement of dystrophic 
muscle by myostatin blockade. Nature 2002;420:418–421. 
Bowles DE, McPhee SW, Li C, et al. Phase 1 gene therapy for Duchenne muscular 
dystrophy using a translational optimized AAV vector. Mol Ther 2012;20:443–455. 
Cirak S, Feng L, Antony K, et al. Restoration of the Dystrophin-associated Glycoprotein 
Complex After Exon Skipping Therapy in Duchenne Muscular Dystrophy. Mol Ther 
2012;20:462–467. 
Falzarano MS, Passarelli C, Ferlini A. Nanoparticle delivery of antisense 
oligonucleotides and their application in the exon skipping strategy for Duchenne 
muscular dystrophy. Nucleic Acid Ther 2014;24:87–100. 
Godfrey C, Muses S, McClorey G, et al. How much dystrophin is enough: the 
physiological consequences of different levels of dystrophin in the mdx mouse. Hum Mol 
Genet. 2015 Aug 1;24(15):4225–4237.  
Griffiths R, Edwards R. A new chart for weight control in Duchenne Muscular 
Dystrophy. Arch Dis Child 1988;63:1256–1258. 
Investigator’s Brochure for SMT C1100. Summit (Oxford) Ltd. Version 9 including 
addendums. 2016. 
Janssen P, Hiranandani N, Mays T, et al. Utrophin deficiency worsens cardiac contractile 
dysfunction present in dystrophin-deficient mdx mice. Am J Physiol Heart Circ Physiol
2005; vol. 289 H2373–2378. 
Kharra Y, Guerra J, Pessina P, et al. Understanding the Process of Fibrosis in Duchenne 
Muscular Dystrophy. Biomed Res Int. 2014;2014:965631 
Kramer J, Obejero-Paz CA, Myatt G, et al. MICE Models: Superior to the HERG Model 
in Predicting Torsade de Pointes. Scientific Reports. 2013;3:2100.  
Mammen A and Sartorelli, V. IL-6 Blockade as a Therapeutic Approach for Duchenne 
Muscular Dystronphy. EBioMedicine 2. 2015: 274-275. 
Mayhew A, Mazzone ES, Eagle M et al. Development of the performance of the upper 
limb module for Duchenne muscular dystrophy. Dec Med Child Neurol. 2013;55:1038–
1045.

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 87 of 89
CONFIDENTIAL
McNally EM, Kaltman JR, Benson DW et al. Contemporary cardiac issues in Duchenne 
muscular dystrophy. Working Group of the National Heart, Lung, and Blood Institute in 
collaboration with Parent Project Muscular Dystrophy. Circulation. 2015;131:1590–1598 
Mercuri E, Muntoni F. Muscular dystrophies. Lancet 2013;381:845–860. 
Merlini L, Sabatelli, P. Improving clinical trial design for Duchenne muscular dystrophy. 
BMC Neurol 2015;15:153. 
Northup P and Caldwell S. Coagulation in Liver Disease: A Guide for the Clinician. 
Clinical Gastroenterology and Hepatology 2013;11:1064–1074. 
Ricotti V, Ridout DA, Scott E, et al. Long-term benefits and adverse effects of 
intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. J 
Neurol Neurosurg Psychiatry 2013;84:698–705. 
Schomaker S, Warner R, Bock J, et al. Assessment of Emerging Biomarkers of Liver 
Injury in Human Subjects. Toxicological Sciences 2013;132:276–283. 
Serra F, Quarta M, Canato M, et al. Inflammation in muscular dystrophy and the 
beneficial effects of non-steroidal anti-inflammatory drugs. Muscle Nerve 2012;46:773–
784.
Sonnemann KJ, Heun-Johnson H, Turner AJ, et al. Functional substitution by TAT-
utrophin in dystrophin-deficient mice. PLoS Med 2009;6:e10000083. 
Tinsley JM, Fairclough RJ, Storer R, et al. Daily treatment with SMT C1100, a novel 
small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in 
the mdx mouse. PLoS One 2011;6:e19189. 
Tinsley JM, Robinson N, Davies KE. Safety, tolerability, and pharmacokinetics of 
SMT C1100, a 2-arylbenzoxazole utrophin modulator, following single- and multiple-
dose administration to healthy male adult volunteers. J Clin Pharmacol 2015;55:698–707. 
Uzark K, King E, Cripe L, et al. Health-related quality of life in children and adolescents 
with Duchenne muscular dystrophy. Pediatrics 2012;13-:e1559–1566. 
Van den Bergen JC, Wokke BH, Janson AA, et al. Dystrophin levels and clinical severity 
in Becker muscular dystrophy patients. J Neurol Neurosurg Psychiatry 2014;85:747–753. 
Wren TA, Bluml S, Tseng-Ong L, Gilsanz V. Three-point technique of fat quantification 
of muscle tissue as a marker of disease progression in Duchenne muscular dystrophy: 
preliminary study. AJR Am J Roentgenol 2008;190:W8–W12. 
Zatz M, Betti RT, Frota-Pessoa O. Treatment of Duchenne muscular dystrophy with 
growth hormone inhibitors. Am J Med Genet 1986;24:549–566. 

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 88 of 89
CONFIDENTIAL
15.
APPENDIX 1: INDUCERS OF CYP1A1, CYP1A2 
SUBSTRATES OF CYP2B6 AND BRCP
Please note, this is not an exhaustive list of inducers of CYP1A1/CYP1A2 or substrates 
of CYP2B6. Please contact your medical monitor for a discussion if in doubt about 
permitted or prohibited medications. 
(1) Inducers of CYP1A1 and CYP1A2 
x
CARBAMAZEPINE 
x
DAILY INTAKE OF CHARGRILLED 
MEAT ABOVE 250 GRAMS/DAY 
x
CRUCIFEROUS VEGETABLES ABOVE 
150 GRAMS/DAY 
x
RIFAMPIN 
x
OMEPRAZOLE 
x
TOBACCO 
(2) CYP2B6 Substrates 
x
CYCLOPHOSPHAMIDE 
x
IFOSFAMIDE 
x
TAMOXIFEN 
x
EFAVIRENZ 
x
NEVIRAPINE 
x
BUPROPION 
x
MEPHOBARBITAL 
x
VALPROIC ACID 
x
MEXILETINE 
x
PROCAINAMIDE 
x
ARTEMISININ 
x
TAZOFELONE 
x
AMINOPYRINE  
x
ANTIPYRINE 
x
PROPOFOL 
x
KETAMINE 
x
PENTOBARBITAL  
x
ROPIVACAINE 
x
LIDOCAINE 
x
SEVOFLURANE 
x
METHADONE 
x
PETHIDINE 
x
SELEGILINE 
x
DIAZEPAM 
x
TEMAZEPAM 
x
CLOTIZAZEPAM 
x
MIDAZOLAM 
x
ESTRONE 
x
TESTOSTERONE 
 

Study Number: SMT C11005
Compound No.: SMT C1100
Protocol
Version:  5.0 24Feb2017
Page 89 of 89
CONFIDENTIAL
(3) BRCP Substrates 
x
IMATINIB 
x
IRINOTECAN 
x
LAPATINIB 
x
ROSUVASTATIN 
x
SULFASALAZINE 
x
TOPOTECAN 
x
OMEPRAZOLE 
x
RABEPRAZOLE 
x
FLUVASTATIN 
x
METHOTREXATE 
x
MITOXANTRONE